Integumentary system disorder
MONDO:0002051A disease involving the integumental system.
Also known as: disease of integumental system, disease or disorder of integumental system, disorder of integumental system, integumental system disease, integumental system disease or disorder, integumentary disease, disorder of integument
4568 clinical trials for this condition and its sub-types, 0 tagged with Integumentary system disorder itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Sub-types of Integumentary system disorder
-
Skin disorder 138 trials · 3,975 incl. sub-types
72 sub-types
- Dermatitis 65 trials · 1,626 incl. sub-types Sub-types →
- Skin neoplasm 170 trials · 994 incl. sub-types Sub-types →
- Hereditary skin disorder 7 trials · 885 incl. sub-types Sub-types →
- Skin disorder caused by infection 3 trials · 350 incl. sub-types Sub-types →
- Systemic sclerosis 261 trials · 295 incl. sub-types Sub-types →
- Chronic ulcer of skin 48 trials · 270 incl. sub-types Sub-types →
- Vesiculobullous skin disease 3 trials · 216 incl. sub-types Sub-types →
- Sweat gland disorder 7 trials · 150 incl. sub-types Sub-types →
- Skin vascular disease 5 trials · 135 incl. sub-types Sub-types →
- Epidermal disease 0 trials · 131 incl. sub-types Sub-types →
- Dermis disorder 0 trials · 103 incl. sub-types Sub-types →
- Sebaceous gland disorder 0 trials · 101 incl. sub-types Sub-types →
- Severe cutaneous adverse reaction 62 trials · 68 incl. sub-types Sub-types →
- Skin pigmentation disorder 12 trials · 63 incl. sub-types Sub-types →
- Lipodystrophy 30 trials · 48 incl. sub-types Sub-types →
- Lichen disease 0 trials · 47 incl. sub-types Sub-types →
- Hereditary epidermal appendage anomaly 0 trials · 45 incl. sub-types Sub-types →
- Rosacea 32 trials Sub-types →
- Keratosis 5 trials · 30 incl. sub-types Sub-types →
- Exanthem 11 trials · 28 incl. sub-types Sub-types →
- Reactive cutaneous fibrous lesion 0 trials · 28 incl. sub-types Sub-types →
- Prurigo nodularis 26 trials
- Toxic dermatosis 0 trials · 20 incl. sub-types Sub-types →
- Pyoderma 2 trials · 16 incl. sub-types Sub-types →
- Hand-foot syndrome 9 trials
- Cutaneous mucinosis 2 trials · 5 incl. sub-types Sub-types →
- Oral erosive lichen 5 trials
- Sunburn 5 trials
- Skin sarcoidosis 3 trials
- Actinic prurigo 2 trials
- Cutaneous sclerosis 2 trials
- Erythema multiforme 2 trials
- Keratosis pilaris 2 trials Sub-types →
- Paronychia 2 trials Sub-types →
- Skin atrophy 2 trials
- Wells syndrome 1 trial
- Aquagenic pruritus 1 trial
- Chronic actinic dermatitis 1 trial
- Erythematosquamous dermatosis 1 trial
- Hand dermatosis 1 trial
- Livedoid vasculopathy 1 trial
- Solar urticaria 1 trial
- Achenbach syndrome 0 trials
- Bazex-Dupre-Christol syndrome 0 trials Sub-types →
- Boudhina Yedes Khiari syndrome 0 trials
- Jessner lymphocytic infiltration of the skin 0 trials
- Nicolau syndrome 0 trials
- Parana hard-skin syndrome 0 trials
- Acquired kinky hair syndrome 0 trials
- Ainhum 0 trials
- Cheilitis glandularis 0 trials
- Congenital lethal erythroderma 0 trials
- Corticosteroid-sensitive aseptic abscess syndrome 0 trials
- Cutaneous pseudolymphoma 0 trials
- Erosive pustular dermatosis of the scalp 0 trials
- Erythema palmare hereditarium 0 trials
- Facial dermatosis 0 trials Sub-types →
- Granuloma faciale 0 trials
- Hematohidrosis 0 trials
- Hyperglobulinemic purpura 0 trials
- Interstitial granulomatous dermatitis with arthritis 0 trials
- Leg dermatosis 0 trials
- Mongolian spot 0 trials
- Multiple benign circumferential skin creases on limbs 0 trials Sub-types →
- Nephrogenic systemic fibrosis 0 trials
- Non-neoplastic nevus 0 trials
- Pellagra 0 trials
- Pityriasis rotunda 0 trials
- Primary cutaneous plasmacytosis 0 trials
- Pseudoxanthoma elasticum-like papillary dermal elastolysis 0 trials
- Scalp dermatosis 0 trials
- Sclerema neonatorum 0 trials
-
Integumentary system cancer 0 trials · 1,088 incl. sub-types
7 sub-types
- Skin cancer 118 trials · 801 incl. sub-types Sub-types →
- Breast adenocarcinoma 36 trials · 279 incl. sub-types Sub-types →
- Atypical lobular breast hyperplasia 11 trials
- Dermatofibrosarcoma protuberans 11 trials Sub-types →
- Bartholin gland carcinoma 0 trials · 1 incl. sub-types Sub-types →
- Breast diffuse large B-cell lymphoma 1 trial
- Nipple carcinoma 0 trials Sub-types →
-
Disorder of pilosebaceous unit 7 trials · 341 incl. sub-types
9 sub-types
- Hair anomaly 0 trials · 228 incl. sub-types Sub-types →
- Sebaceous gland disorder 0 trials · 101 incl. sub-types Sub-types →
- Folliculitis 1 trial · 8 incl. sub-types Sub-types →
- Hypotrichosis 5 trials · 6 incl. sub-types Sub-types →
- Piedra 0 trials · 2 incl. sub-types Sub-types →
- Katsantoni-Papadakou-Lagoyanni syndrome 0 trials
- Hair follicle neoplasm 0 trials Sub-types →
- Hypertrichosis 0 trials Sub-types →
- Trichostasis spinulosa 0 trials
-
Skin appendage disorder 0 trials · 244 incl. sub-types
4 sub-types
- Hair anomaly 0 trials · 228 incl. sub-types Sub-types →
- Epidermal appendage tumor 3 trials · 8 incl. sub-types Sub-types →
- Internal hordeolum 1 trial · 6 incl. sub-types Sub-types →
- Piedra 0 trials · 2 incl. sub-types Sub-types →
-
Integumentary system benign neoplasm 0 trials · 121 incl. sub-types
8 sub-types
- Benign neoplasm of skin 3 trials · 118 incl. sub-types Sub-types →
- Adiposis dolorosa 2 trials
- Intraductal breast papilloma 1 trial Sub-types →
- Bartholin gland benign neoplasm 0 trials Sub-types →
- Adenoma of nipple 0 trials
- Familial multiple lipomatosis 0 trials
- Hemangioma of subcutaneous tissue 0 trials
- Multiple symmetric lipomatosis 0 trials Sub-types →
-
Cutaneous mycosis 1 trial · 118 incl. sub-types
5 sub-types
- Tinea infection 1 trial · 116 incl. sub-types Sub-types →
- Superficial mycosis 0 trials · 88 incl. sub-types Sub-types →
- Dermatomycosis 1 trial Sub-types →
- Cutaneous basidiobolomycosis 0 trials
- Subcutaneous mycosis 0 trials Sub-types →
-
Subcutaneous tissue disorder 0 trials · 64 incl. sub-types
19 sub-types
- Lipedema 41 trials
- Fibrodysplasia ossificans progressiva 10 trials
- Cerebrotendinous xanthomatosis 6 trials
- CLOVES syndrome 5 trials
- Adiposis dolorosa 2 trials
- Mycetoma 1 trial
- Nodular non-suppurative panniculitis 1 trial
- FLOTCH syndrome 0 trials
- Pierpont syndrome 0 trials
- Roch-Leri mesosomatous lipomatosis 0 trials
- Cytophagic histiocytic panniculitis 0 trials
- Dissecting cellulitis of the scalp 0 trials
- Encephalocraniocutaneous lipomatosis 0 trials
- Familial angiolipomatosis 0 trials
- Familial multiple lipomatosis 0 trials
- Hemangioma of subcutaneous tissue 0 trials
- Isolated anhidrosis with normal sweat glands 0 trials
- Multiple symmetric lipomatosis 0 trials Sub-types →
- Nodular fasciitis 0 trials Sub-types →
-
Cutis laxa 37 trials · 39 incl. sub-types
2 sub-types
- Inherited cutis laxa 0 trials · 2 incl. sub-types Sub-types →
- Acquired cutis laxa 0 trials
-
X-linked ichthyosis syndrome 0 trials · 37 incl. sub-types
2 sub-types
- CHILD syndrome 37 trials
- Syndromic recessive X-linked ichthyosis 0 trials
-
Keratinization disease 1 trial · 31 incl. sub-types
2 sub-types
- Keratosis 5 trials · 30 incl. sub-types Sub-types →
- Epidermolytic ichthyosis 1 trial Sub-types →
-
Nail disorder 2 trials · 18 incl. sub-types
7 sub-types
- Nail infection 0 trials · 14 incl. sub-types Sub-types →
- Paronychia 2 trials Sub-types →
- Basaran Yilmaz syndrome 0 trials
- Judge Misch wright syndrome 0 trials
- Inherited isolated nail anomaly 0 trials Sub-types →
- Nail anomaly 0 trials
- Nail tumor 0 trials Sub-types →
-
Pseudoxanthoma elasticum (inherited or acquired) 5 trials · 7 incl. sub-types
2 sub-types
- Inherited pseudoxanthoma elasticum 0 trials · 7 incl. sub-types Sub-types →
- Acquired pseudoxanthoma elasticum 0 trials
-
Demodicidosis 5 trials · 6 incl. sub-types
2 sub-types
- Demodex folliculitis 5 trials
- Demodicidosis of sebaceous gland 0 trials
-
Panniculitis 3 trials · 6 incl. sub-types
6 sub-types
- Lipodermatosclerosis 1 trial
- Nodular non-suppurative panniculitis 1 trial
- Panniculitis and localized lipodystrophy 1 trial
- Cytophagic histiocytic panniculitis 0 trials
- Erythema nodosum 0 trials
- Lupus erythematosus panniculitis 0 trials
-
Mucosulfatidosis 4 trials
-
Sjogren-Larsson syndrome 3 trials
-
1 sub-type
- Melanoma-pancreatic cancer syndrome 0 trials
-
Breast fibrosis 2 trials
-
Rombo syndrome 1 trial
-
Familial tumoral calcinosis 1 trial
5 sub-types
- Familial hyperphosphatemic tumoral calcinosis/hyperphosphatemic hyperostosis syndrome 0 trials
- Normophosphatemic familial tumoral calcinosis 0 trials
- Tumoral calcinosis, hyperphosphatemic, familial, 1 0 trials
- Tumoral calcinosis, hyperphosphatemic, familial, 2 0 trials
- Tumoral calcinosis, hyperphosphatemic, familial, 3 0 trials
-
Ichthyosis prematurity syndrome 1 trial
-
Bartholin gland neoplasm 0 trials · 1 incl. sub-types
2 sub-types
- Bartholin gland carcinoma 0 trials · 1 incl. sub-types Sub-types →
- Bartholin gland benign neoplasm 0 trials Sub-types →
-
ANE syndrome 0 trials
-
Bartholin duct cyst 0 trials
-
Neu-Laxova syndrome 0 trials
3 sub-types
- Neu-Laxova syndrome 1 0 trials
- Neu-Laxova syndrome 2 0 trials
- Neu-laxova syndrome due to 3-phosphoserine phosphatase deficiency 0 trials
-
Proteus-like syndrome 0 trials
-
Benign mammary dysplasia 0 trials
-
Keratoderma hereditarium mutilans 0 trials
-
Nipple neoplasm 0 trials
3 sub-types
- Adenoma of nipple 0 trials
- Infiltrating nipple syringomatous adenoma 0 trials
- Nipple carcinoma 0 trials Sub-types →
-
Paraneoplastic cutaneous syndrome 0 trials
1 sub-type
- Paraneoplastic pemphigus 0 trials
Most studied deeper sub-types
Showing the 400 most recently updated of 859 trials in this tab.
-
Rewriting the code: a One-Time gene fix for a rare immune disease?
Cure By invitation onlyThis trial tests a one-time gene therapy for WHIM syndrome, a rare inherited immune disorder that causes severe infections. Doctors collect a person's own blood stem cells, use base editing to correct the faulty CXCR4 gene, and return the edited cells to the body. The goal is to …
Phase 1/2 • Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Cure
Last updated Sep 21, 2026 21:00 UTC
-
Immunotherapy before surgery tested against aggressive skin cancer
Cure OngoingResearchers are testing whether giving the immunotherapy drug cemiplimab before and after surgery can help patients with high-risk cutaneous squamous cell carcinoma, a type of skin cancer. The trial enrolls people whose cancer has features that raise the risk of it coming back, s…
Phase 1 • Sponsor: Emory University • Aim: Cure
Last updated Sep 16, 2026 00:00 UTC
-
Lab-Grown skin could transform burn care for children
Cure OngoingThis trial is testing a lab-grown skin substitute called denovoSkin in children with deep burns. The engineered skin is made from the child's own cells and is compared to the standard treatment of using a split-thickness skin graft. The goal is to see if denovoSkin can cover burn…
Phase 2 • Sponsor: CUTISS AG • Aim: Cure
Last updated Aug 08, 2026 00:03 UTC
-
Sound waves zapping skin cancer? new trial tests HIFU for basal cell carcinoma
Cure OngoingThis trial tests a new device that uses high-intensity focused ultrasound (HIFU) to treat basal cell carcinoma, the most common skin cancer. Forty adults with either new or recurring skin cancers will receive a single 3-5 minute treatment. Researchers will check if the cancer is …
Sponsor: Joergen Serup • Aim: Cure
Last updated Jun 27, 2026 07:53 UTC
-
New drug shows promise for Long-Term control of rare muscle disease
Disease control By invitation onlyThis study tests the long-term safety of a drug called efgartigimod PH20 SC in adults with active idiopathic inflammatory myopathy, a group of rare muscle diseases. Participants who completed a previous trial will receive the drug as a shot under the skin for up to 51 months. The…
Phase 3 • Sponsor: argenx • Aim: Disease control
Last updated Sep 21, 2026 21:00 UTC
-
New drug aims to tame muscle inflammation in myositis
Disease control OngoingThis phase 2 trial tests whether nipocalimab, given intravenously, can improve symptoms of active idiopathic inflammatory myopathies (myositis) better than a placebo. About 36 adults with myositis will receive either nipocalimab or a placebo, along with standard steroid treatment…
Phase 2 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Sep 21, 2026 21:00 UTC
-
Can red light heal bedsores faster? new trial aims to find out
Disease control By invitation onlyThis study tests whether shining a specific red light on bedsores (pressure ulcers) can help them heal faster. About 46 ICU patients with stage II bedsores will either get the light treatment plus standard care, or standard care alone, for 14 days. Researchers will track wound si…
Sponsor: Ankara Medipol University • Aim: Disease control
Last updated Sep 21, 2026 21:00 UTC
-
Real-World hair loss drug study launches: will ritlecitinib deliver in practice?
Disease control OngoingThis study follows 850 people with alopecia areata who are taking the approved drug ritlecitinib in real-world clinics. Researchers will measure hair regrowth using the SALT score over 24 weeks. The goal is to see how well the drug works outside of controlled trials, in everyday …
Sponsor: Pfizer • Aim: Disease control
Last updated Sep 21, 2026 21:00 UTC
-
Immune system overhaul: could CAR T-Cells tame autoimmune disease?
Disease control OngoingThis early-stage trial is testing a new treatment called KYV-101 for people with severe autoimmune diseases like lupus, scleroderma, and vasculitis. The treatment involves taking a patient's own immune cells, modifying them to target and destroy faulty B cells, and giving them ba…
Phase 1 • Sponsor: David Porter • Aim: Disease control
Last updated Sep 21, 2026 21:00 UTC
-
New pill could tame tough psoriasis
Disease control OngoingThis phase 3 trial tests an oral drug called JNJ-77242113 in 774 adults with moderate to severe plaque psoriasis. Participants receive either the new drug, a placebo, or an active comparator (deucravacitinib) to see how well it clears skin lesions. The main goal is to measure imp…
Phase 3 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Sep 21, 2026 21:00 UTC
-
New combo shows promise in shrinking melanoma before surgery
Disease control OngoingThis study tests whether adding an experimental drug (CMP-001) to the immunotherapy pembrolizumab can better shrink melanoma tumors before surgery and help prevent them from coming back. About 60 adults with stage III or recurrent melanoma that can be surgically removed will rece…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 21, 2026 21:00 UTC
-
New drug duo targets Hard-to-Treat lymphomas
Disease control OngoingThis early-stage trial tests the safety and best dose of combining two drugs, tazemetostat and belinostat, for people with lymphoma that has returned or stopped responding to standard treatments. The study includes about 48 adults with various types of non-Hodgkin lymphoma. Resea…
Phase 1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
New psoriasis drug shows promise for kids in Head-to-Head trial
Disease control OngoingThis study tests a new medicine called bimekizumab against an existing one (ustekinumab) for children and teens aged 6 to 17 with moderate to severe plaque psoriasis. The goal is to see if bimekizumab works better at clearing skin symptoms. About 168 participants will receive inj…
Phase 3 • Sponsor: UCB Biopharma SRL • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
Gene therapy shot aims to tame autoimmune diseases in early trial
Disease control OngoingThis early-phase study tests a single injection of a gene therapy called V001-BCMA for people with autoimmune diseases like lupus that have not responded to standard treatments. The therapy targets and modifies specific immune cells to reduce disease activity. The main goal is to…
Early phase 1 • Sponsor: Tongji Hospital • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
Can a rheumatoid arthritis drug tame Immunotherapy's side effects?
Disease control OngoingThis study tests whether adding tocilizumab (a drug used for arthritis) to standard immunotherapy can reduce severe side effects in people with advanced melanoma, lung cancer, or bladder cancer. About 35 participants will receive all three drugs. The goal is to see if the combina…
Phase 2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
Hope for rare fat disorder: drug keeps working in Long-Term study
Disease control OngoingThis study gives the drug metreleptin to 29 people with partial lipodystrophy, a rare condition that causes high blood fats and diabetes. Participants have already shown improvement from the drug in earlier studies. The goal is to keep providing the treatment and check its long-t…
Phase 2 • Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
Lifesaving drug made available for rare fat disorder patients
Disease control OngoingThis study gives the drug metreleptin to people with generalized lipodystrophy, a rare condition that causes severe fat loss and leads to high blood fats and diabetes. Participants, aged 6 months and older, have already received metreleptin in past NIH studies but cannot get it i…
Phase 3 • Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
Hair loss pill for women? new trial tests oral minoxidil
Disease control OngoingThis phase 3 trial tests whether a daily 1 mg minoxidil pill can treat female pattern hair loss as effectively as the standard topical minoxidil solution. About 520 women with hair thinning will be randomly assigned to receive either the oral pill, the topical solution, or a plac…
Phase 3 • Sponsor: Industrial Farmacéutica Cantabria, S.A. • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
New pill shows promise for rare skin cancer in early trial
Disease control OngoingThis early-phase trial tests a new drug called tulmimetostat (DZR123) in 24 people with advanced mycosis fungoides or Sézary syndrome, rare types of skin lymphoma. Participants must have tried at least one prior treatment. The study aims to see if the drug is safe and tolerable, …
Phase 1 • Sponsor: Washington University School of Medicine • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
Immune cell therapy takes on tough scleroderma
Disease control OngoingThis early trial tests whether a single infusion of anti-CD19 CAR T-cells can improve skin thickening and other symptoms in 6 adults with severe, treatment-resistant systemic sclerosis. Participants receive chemotherapy before the infusion and are monitored for 24 months. The stu…
Phase 2 • Sponsor: University Hospital, Montpellier • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
Can a skin cream bring back color to faces with vitiligo?
Disease control OngoingResearchers are testing a cream called delgocitinib on facial vitiligo, a condition where skin loses its color in patches. Twelve adults with non-segmental vitiligo on the face will apply the cream twice daily for 24 weeks. The trial measures changes in the size and severity of w…
Phase 2 • Sponsor: Lone Skov • Aim: Disease control
Last updated Sep 17, 2026 00:00 UTC
-
New acne gel put to the test for Year-Long safety
Disease control OngoingThis study is testing whether a new gel applied daily for up to 52 weeks is safe for people with acne. About 400 participants will use the gel on their face and upper body and visit the clinic regularly for checkups. The main goal is to track any side effects, not to measure how …
Phase 3 • Sponsor: PPM Services S.A. • Aim: Disease control
Last updated Sep 17, 2026 00:00 UTC
-
Could taking a break from melanoma drugs be just as good?
Disease control OngoingThis phase 2 trial compares two ways of taking the targeted drugs dabrafenib and trametinib for advanced BRAF-mutant melanoma: continuously versus with planned breaks. About 280 people with stage III or IV melanoma that cannot be surgically removed are participating. The goal is …
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 17, 2026 00:00 UTC
-
Walk or cycle before cancer treatment: new study tests exercise boost
Disease control OngoingThis early-phase study tests whether 30 minutes of moderate exercise (like walking or cycling) right before standard immunotherapy can improve treatment for certain skin cancers (melanoma, squamous cell carcinoma, Merkel cell carcinoma). About 22 adults will exercise before each …
Early phase 1 • Sponsor: H. Lee Moffitt Cancer Center and Research Institute • Aim: Disease control
Last updated Sep 17, 2026 00:00 UTC
-
New drug cocktail shows promise in early cancer trial
Disease control OngoingThis phase 1 trial is testing the safety and best dose of a combination of three drugs—entinostat, nivolumab, and ipilimumab—in people with advanced solid tumors that have spread or cannot be removed. The goal is to see if this mix can help the immune system fight cancer more eff…
Phase 1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 17, 2026 00:00 UTC
-
New drug shows promise for painful skin condition
Disease control OngoingThis study tests a new drug called tulisokibart in 147 people with moderate to severe hidradenitis suppurativa, a chronic skin condition causing painful lumps. Participants are randomly assigned to receive either the drug or a placebo, and researchers will check if the drug reduc…
Phase 2 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Sep 17, 2026 00:00 UTC
-
New study aims to spare healthy breast tissue during cancer surgery
Disease control OngoingThis study compares two surgical approaches for breast cancer: one that removes extra tissue around the tumor (routine cavity shave margins) and one that uses a special device (Savi Scout®) to guide removal of only suspicious margins. About 204 women with early-stage breast cance…
Sponsor: Case Comprehensive Cancer Center • Aim: Disease control
Last updated Sep 17, 2026 00:00 UTC
-
Scientists probe whether lebrikizumab rewires diseased skin at the molecular level
Disease control OngoingResearchers are studying lebrikizumab, an approved injectable drug for atopic dermatitis, to understand how it changes skin biology over time. The trial enrolls 48 people with moderate-to-severe atopic dermatitis who have not done well on topical treatments. Participants receive …
Phase 4 • Sponsor: Johann E Gudjonsson MD PhD • Aim: Disease control
Last updated Sep 17, 2026 00:00 UTC
-
PET scans may let melanoma patients stop treatment sooner
Disease control OngoingThis study looks at whether doctors can safely stop standard anti-PD-1 immunotherapy early in people with advanced melanoma that cannot be surgically removed. By using PET/CT scans and tumor biopsies as guides, the goal is to reduce treatment side effects and burden without harmi…
Phase 2 • Sponsor: ECOG-ACRIN Cancer Research Group • Aim: Disease control
Last updated Sep 17, 2026 00:00 UTC
-
New pill aims to tame rare immune diseases
Disease control OngoingThis early-stage trial tests an experimental drug called BI 3000202 in 16 adults with rare type 1 interferonopathies, such as Aicardi-Goutières syndrome. Participants take a low dose for 4 weeks, then a higher dose for 36 weeks. The main goal is to see if the drug is safe and how…
Phase 1 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Sep 17, 2026 00:00 UTC
-
New drug combo targets Hard-to-Treat cancers in early trial
Disease control OngoingThis early-phase trial tested the safety and best dose of two drugs—riluzole and sorafenib—given together to people with advanced solid tumors or melanoma that had spread and stopped responding to standard treatments. The goal was to find the highest safe dose and see if the comb…
Phase 1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 17, 2026 00:00 UTC
-
Can a cancer vaccine injections clear warts that Won't go away?
Disease control OngoingThis phase 2 trial tests whether Gardasil-9, a vaccine normally used to prevent HPV infection, can treat warts that have not responded to standard treatments. Researchers inject the vaccine directly into the wart, rather than into a muscle, and compare its effect against a placeb…
Phase 2 • Sponsor: Rush University Medical Center • Aim: Disease control
Last updated Sep 17, 2026 00:00 UTC
-
Radiation plus immunotherapy: a new hope for advanced head and neck cancer?
Disease control OngoingThis phase III trial compares the standard immunotherapy drug pembrolizumab alone versus pembrolizumab plus radiation therapy in 290 patients with metastatic head and neck cancer. The goal is to see if adding radiation improves overall survival. Participants receive pembrolizumab…
Phase 3 • Sponsor: ECOG-ACRIN Cancer Research Group • Aim: Disease control
Last updated Sep 16, 2026 00:00 UTC
-
New radiation approach aims to cut treatment time and side effects for breast cancer
Disease control PausedThis study tests a shorter, more focused radiation treatment (hypofractionated partial breast irradiation) for women with early-stage breast cancer. The goal is to see if targeting only the tumor site can reduce side effects and improve cosmetic outcomes compared to standard whol…
Phase 2/3 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Sep 16, 2026 00:00 UTC
-
Cold plasma could speed up healing of chronic wounds
Disease control OngoingThis study tests whether adding cold plasma therapy to standard wound care helps heal large chronic leg ulcers faster. About 120 adults with non-healing wounds will receive either standard care alone or standard care plus a 4-week plasma treatment. The main goal is to see if the …
Sponsor: Coldplasmatech • Aim: Disease control
Last updated Sep 16, 2026 00:00 UTC
-
Immune cocktail shows promise for Tough-to-Treat melanoma
Disease control OngoingThis phase II trial tests whether adding a growth factor (GM-CSF) to the immunotherapy drug ipilimumab helps people with advanced melanoma live longer. About 245 patients with stage III or IV melanoma that cannot be surgically removed are randomly assigned to get ipilimumab alone…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 16, 2026 00:00 UTC
-
Could less be more? new trial tests gentler treatment for anal cancer
Disease control OngoingThis phase II trial is testing whether a lower dose of chemotherapy plus radiation can work as well as the standard dose for early-stage anal cancer. The study includes 252 adults with T1-2N0M0 anal cancer. The goal is to see if the gentler approach controls the disease while imp…
Phase 2 • Sponsor: ECOG-ACRIN Cancer Research Group • Aim: Disease control
Last updated Sep 16, 2026 00:00 UTC
-
New hope for rare cancers: drug duo shows promise
Disease control OngoingThis phase II trial tests whether combining two drugs, atezolizumab and bevacizumab, can shrink rare solid tumors like appendix cancer, anal cancer, and mesothelioma. About 133 participants with various rare cancers will receive the drugs intravenously. The goal is to see if the …
Phase 2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Sep 16, 2026 00:00 UTC
-
Experimental CART123 therapy targets tough blood cancers in early trial
Disease control OngoingThis early-phase trial tests a personalized cell therapy called CART123 for people with certain blood cancers (like AML or MDS) that have not responded to standard treatments. Each patient's own immune cells are modified in a lab to recognize and attack cancer cells. The main goa…
Early phase 1 • Sponsor: Institute of Hematology and Blood Transfusion, Czech Republic • Aim: Disease control
Last updated Sep 16, 2026 00:00 UTC
-
Experimental drug dinaciclib tested in advanced melanoma patients
Disease control OngoingThis phase II trial is testing the drug dinaciclib in 72 people with stage IV melanoma that has spread. The drug works by blocking enzymes that help cancer cells grow. Researchers are looking at side effects and whether it helps patients live longer or slows tumor growth.
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 16, 2026 00:00 UTC
-
New dye could spare thousands of women from unnecessary lymph node removal
Disease control PausedThis study tests a new dye called Magtrace that stays in the lymph nodes for weeks. For women with non-invasive breast cancer (DCIS) having a mastectomy, this dye may allow doctors to safely delay lymph node removal until after the breast tissue is checked for hidden invasive can…
Phase 2 • Sponsor: University of Florida • Aim: Disease control
Last updated Sep 13, 2026 00:00 UTC
-
Can a Drug-Radiation combo outsmart Treatment-Resistant colorectal cancer?
Disease control CancelledThis phase 2 trial is testing whether combining an experimental drug called S-531011 with a precise radiation technique known as RadScopal can help control metastatic colorectal cancer that has not responded to prior treatments. The study enrolls about 30 adults with advanced dis…
Phase 2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Sep 13, 2026 00:00 UTC
-
New hope for teens with severe skin disease: drug trial launches
Disease control OngoingThis study tests a drug called bimekizumab in teenagers (ages 9 to 17) with moderate to severe hidradenitis suppurativa, a painful skin condition that causes boils. The goal is to see how the drug moves through the body and if it is safe. About 40 participants will receive the dr…
Phase 3 • Sponsor: UCB Biopharma SRL • Aim: Disease control
Last updated Sep 13, 2026 00:00 UTC
-
Immunotherapy after Chemo-Radiation may keep anal cancer at bay
Disease control OngoingThis phase III trial tests whether adding the immunotherapy drug nivolumab after standard combined modality therapy (chemo and radiation) can improve outcomes for patients with high-risk stage IIB-IIIC anal cancer. About 344 participants will receive nivolumab or a placebo. The m…
Phase 3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 12, 2026 00:00 UTC
-
New drug aims to tame scleroderma in major trial
Disease control OngoingThis Phase 3 study tests whether anifrolumab, given as a weekly shot, can improve symptoms of systemic sclerosis (scleroderma) compared to a placebo. About 314 adults aged 18-70 with early-stage disease will take part. The main goal is to see if more people respond to treatment, …
Phase 3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Sep 12, 2026 00:00 UTC
-
New drug bitopertin offers hope for sunlight pain relief in rare blood disorders
Disease control By invitation onlyThis long-term study tests the safety and effectiveness of bitopertin (DISC-1459) in people with erythropoietic protoporphyria (EPP) or X-linked protoporphyria (XLP), rare conditions that cause severe pain from sunlight exposure. About 230 participants who previously took bitoper…
Phase 2/3 • Sponsor: Disc Medicine, Inc • Aim: Disease control
Last updated Sep 12, 2026 00:00 UTC
-
Could dead donors provide Life-Saving bone marrow?
Disease control OngoingThis early study is testing whether bone marrow from deceased donors can be safely used for transplants in people with blood cancers like leukemia and lymphoma. Twelve patients will receive the transplant along with chemotherapy or radiation. The main goal is to see if the new ma…
Phase 1/2 • Sponsor: Ossium Health, Inc. • Aim: Disease control
Last updated Sep 12, 2026 00:00 UTC
-
New oral drug shows promise for rare sun allergy conditions
Disease control OngoingThis study is for people with erythropoietic protoporphyria (EPP) or X-linked protoporphyria (XLP), rare conditions that cause severe pain and skin reactions to sunlight. The purpose is to check the long-term safety of an oral medication called dersimelagon. About 301 participant…
Phase 3 • Sponsor: Tanabe Pharma America, Inc. • Aim: Disease control
Last updated Sep 11, 2026 00:00 UTC
-
Could a malaria drug help fight cancer? early trial tests new combo
Disease control OngoingThis early-phase trial tests two drugs together—MK-2206 and hydroxychloroquine—in people with advanced solid tumors, melanoma, kidney, or prostate cancer. The goal is to find the safest dose and see how the combination affects cancer cell growth. About 62 participants will take b…
Phase 1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 11, 2026 00:00 UTC
-
Major trial tests ipilimumab against standard therapy for High-Risk melanoma
Disease control OngoingThis phase 3 trial tests whether the immunotherapy drug ipilimumab is better than high-dose interferon alfa-2b at preventing melanoma from coming back in patients whose cancer was removed by surgery. Over 1,600 people with high-risk stage III or IV melanoma took part. The study m…
Phase 3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 10, 2026 00:00 UTC
-
New hope for rare cancer: immune booster plus chemo shows promise
Disease control OngoingThis phase II trial tests whether adding the immunotherapy drug nivolumab to the chemotherapy paclitaxel helps shrink tumors in people with angiosarcoma who haven't had taxane drugs before. For those who have already received taxanes, the trial tests a combination of nivolumab an…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 10, 2026 00:00 UTC
-
Engineered immune cells take on rare autoimmune disease in kids
Disease control PausedThis early-stage trial tests whether a type of immunotherapy called CAR-T cells can safely treat children with severe systemic sclerosis, a rare autoimmune disease that causes skin thickening and organ damage. The treatment involves collecting the child's own immune cells, engine…
Phase 1 • Sponsor: The Children's Hospital of Zhejiang University School of Medicine • Aim: Disease control
Last updated Sep 10, 2026 00:00 UTC
-
New eczema drug combo enters early human testing
Disease control OngoingThis early-stage trial is testing a combination of two experimental drugs, APG777 and APG990, in 86 adults with moderate-to-severe atopic dermatitis (eczema). The main goal is to check safety and how the drugs move through the body, comparing them to the existing treatment Dupixe…
Phase 1 • Sponsor: Apogee Therapeutics, Inc. • Aim: Disease control
Last updated Sep 10, 2026 00:00 UTC
-
Landmark trial may spare thousands of women from chemo
Disease control OngoingThis large phase 3 trial studied over 10,000 women with early-stage, hormone-receptor-positive breast cancer that hasn't spread to lymph nodes. It used the Oncotype DX test to assign women to hormone therapy alone or hormone therapy plus chemotherapy based on their recurrence sco…
Phase 3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 10, 2026 00:00 UTC
-
Personalized mRNA vaccine shows promise in fighting melanoma return
Disease control OngoingThis phase 2 trial is testing whether adding a personalized mRNA cancer vaccine (mRNA-4157) to the immunotherapy drug pembrolizumab can better prevent melanoma from coming back after surgery compared to pembrolizumab alone. The study involves 267 people with high-risk melanoma th…
Phase 2 • Sponsor: ModernaTX, Inc. • Aim: Disease control
Last updated Sep 10, 2026 00:00 UTC
-
Could allergy pills calm irritable bowel syndrome?
Disease control CancelledThis trial tests whether a combination of two common antihistamines, cetirizine and famotidine, can reduce symptoms in people with diarrhea-predominant irritable bowel syndrome (IBS-D). Participants take the antihistamines or a placebo for 30 days, then switch, so each person ser…
Phase 3 • Sponsor: University of Cincinnati • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC
-
Can a new injection tame hereditary swelling attacks?
Disease control ApprovedThis program provides access to an investigational drug called donidalorsen for people with hereditary angioedema (HAE), a genetic condition that causes sudden, painful swelling in various body parts. The drug is given as a monthly or every-other-month injection under the skin. I…
Sponsor: Ionis Pharmaceuticals, Inc. • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC
-
Can a targeted drug hit the mark in Hard-to-Treat blood cancers?
Disease control OngoingThis trial tests an experimental drug called IMGN632 in people with certain blood cancers, including acute myeloid leukemia and blastic plasmacytoid dendritic cell neoplasm. The drug is designed to find and attack cancer cells that carry a protein called CD123 on their surface. R…
Phase 1/2 • Sponsor: AbbVie • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC
-
Could removing certain immune cells prevent a deadly transplant complication?
Disease control OngoingThis study tests whether removing a specific type of immune cell (naive T cells) from donor stem cells can prevent chronic graft-versus-host disease (GVHD) in children and young adults with blood cancers. GVHD occurs when donor cells attack the patient's body after a stem cell tr…
Phase 2 • Sponsor: Fred Hutchinson Cancer Center • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
New mRNA vaccine shows promise in fighting solid tumors
Disease control OngoingThis early-stage trial tests an experimental mRNA-based cancer vaccine (mRNA-4157) in 161 people with solid tumors. The vaccine is designed to train the immune system to attack cancer cells. Some participants receive the vaccine alone, while others get it with the immunotherapy d…
Phase 1 • Sponsor: ModernaTX, Inc. • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
Triple threat: new drug cocktail targets tough melanoma
Disease control OngoingThis study tests whether adding two targeted pills (encorafenib and binimetinib) to standard immunotherapy (pembrolizumab) works better than immunotherapy alone for people with advanced melanoma that has a BRAF gene mutation. About 257 adults with untreated, advanced or spreading…
Phase 3 • Sponsor: Pfizer • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
Could a skin gel help fight breast cancer? early trial tests endoxifen
Disease control OngoingThis early-phase trial is testing a gel form of the drug endoxifen, applied to the skin, in 32 women scheduled for breast surgery. The goal is to see if the gel is safe and how much of the drug gets into breast tissue and blood. If successful, it might offer a gentler way to trea…
Phase 1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC
-
New drug hope for scleroderma patients with lung complications
Disease control OngoingThis study tests an experimental drug called ifetroban in 34 adults with a severe form of scleroderma (diffuse cutaneous systemic sclerosis) or scleroderma-related lung disease (pulmonary arterial hypertension). The main goal is to see if the drug is safe and whether it can impro…
Phase 2 • Sponsor: Cumberland Pharmaceuticals • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC
-
New hope for advanced tumors: drug trial targets untreated patients
Disease control OngoingThis study tests a new drug called INCB099280 in 73 people with advanced solid tumors who have not received immunotherapy before. The goal is to see if the drug can shrink tumors and to check for side effects. The study focuses on safety and how well the drug works in the short t…
Phase 2 • Sponsor: Incyte Corporation • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC
-
Can a cancer drug stop the body from making extra bone?
Disease control OngoingThis phase 2 trial tests whether saracatinib, an oral drug originally developed for cancer, can prevent new abnormal bone growth in adults with fibrodysplasia ossificans progressiva (FOP), a rare genetic condition where muscle and soft tissue turn into bone. Twenty adults with ac…
Phase 2 • Sponsor: Amsterdam UMC, location VUmc • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC
-
New pill could let Sun-Sensitive patients enjoy the outdoors
Disease control OngoingThis Phase 3 trial tests whether bitopertin, a daily pill, can help people with erythropoietic protoporphyria (EPP) or X-linked protoporphyria (XLP) spend more time in sunlight without pain. About 183 participants aged 12 and older will take bitopertin or a placebo for 6 months. …
Phase 3 • Sponsor: Disc Medicine, Inc • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC
-
New liposome chemo shows promise in early cancer trial
Disease control OngoingThis early-stage trial tests FF-10850, a liposome-wrapped version of the chemotherapy drug topotecan, in 96 adults with advanced solid tumors like ovarian, cervical, and Merkel cell carcinoma. The main goals are to find the safest dose and understand side effects. Researchers hop…
Phase 1 • Sponsor: Fujifilm Pharmaceuticals U.S.A., Inc. • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC
-
Laser light shows promise for thinning hair in new trial
Disease control OngoingThis study is testing a device called Ultra that uses low-level laser light to help hair grow back. It involves 44 adults aged 22 to 70 with male or female pattern baldness. Participants will receive six laser treatments on their scalp, two weeks apart, and researchers will check…
Sponsor: CynosureLutronic • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC
-
New drug lutikizumab aims to ease painful skin lumps in major trial
Disease control OngoingThis phase 3 trial tests the drug lutikizumab against a placebo in about 1400 adults and teens with moderate to severe hidradenitis suppurativa, a chronic skin condition causing painful lumps and abscesses. Participants receive weekly shots for 16 weeks, then continue on differen…
Phase 3 • Sponsor: AbbVie • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC
-
New triple-drug attack aims to revive immune response in hard-to-treat melanoma
Disease control OngoingThis phase 2 trial tests whether combining high-dose interleukin-2 with low-dose ipilimumab, followed by nivolumab, can shrink tumors in people with advanced melanoma that has stopped responding to prior immunotherapy. About 29 participants with inoperable stage III or IV melanom…
Phase 2 • Sponsor: H. Lee Moffitt Cancer Center and Research Institute • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC
-
Could a lower tamoxifen dose be just as good for Low-Risk breast cancer?
Disease control PausedThis phase III trial compares low-dose tamoxifen to standard hormone therapy (aromatase inhibitors) in postmenopausal women with low-risk, hormone-positive, HER2-negative early breast cancer. The goal is to see if the lower dose works just as well to prevent cancer from coming ba…
Phase 3 • Sponsor: Alliance for Clinical Trials in Oncology • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC
-
Can a single infusion stop GPP flares in their tracks?
Disease control OngoingThis study is testing whether the drug spesolimab can safely and effectively treat repeated flares of generalized pustular psoriasis (GPP), a serious skin condition. Adults with GPP who have had a flare will receive a single intravenous dose of spesolimab, with a possible second …
Phase 4 • Sponsor: LEO Pharma • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC
-
One-Time cell therapy aims to tame tough scleroderma
Disease control OngoingThis study tests a new treatment called rapcabtagene autoleucel, made from a patient's own immune cells, for people with severe scleroderma that hasn't improved with standard care. About 96 participants will receive either this one-time cell therapy or the current drug rituximab.…
Phase 2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC
-
Could shedding pounds after breast cancer keep the disease away?
Disease control OngoingThis phase III trial tests whether a structured weight loss program can lower the risk of breast cancer recurrence in overweight or obese women who have been treated for early-stage breast cancer. Researchers will compare women who join the program with those who do not, tracking…
Phase 3 • Sponsor: Alliance for Clinical Trials in Oncology • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC
-
Could a Pre-Surgery immune booster beat standard care for skin cancer?
Disease control PausedThis phase III trial compares adding the immunotherapy drug cemiplimab before surgery (with or without radiation) to standard surgery alone for people with stage III/IV squamous cell skin cancer that can be removed. The goal is to see if the combination improves event-free surviv…
Phase 3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 03, 2026 00:00 UTC
-
New hope for chronic mouth condition: baricitinib trial launches
Disease control OngoingThis study tests whether baricitinib, a drug used for arthritis, can help people with moderate to severe oral lichen planus—a painful mouth condition. Ten adults who haven't improved with other treatments will take the drug for six months. Researchers will measure changes in mout…
Phase 2 • Sponsor: University of North Carolina, Chapel Hill • Aim: Disease control
Last updated Sep 03, 2026 00:00 UTC
-
New pill could ease painful skin lumps for those failed by antibiotics
Disease control OngoingThis study tests a daily pill called ritlecitinib for adults with moderate to severe hidradenitis suppurativa (HS), a condition causing painful red skin lumps. About 240 participants who haven't been helped by antibiotics will be randomly assigned to get the drug or a placebo for…
Phase 2 • Sponsor: Pfizer • Aim: Disease control
Last updated Sep 03, 2026 00:00 UTC
-
New drug shows promise for rare skin disease over nearly 5 years
Disease control OngoingThis study looks at the long-term safety and effectiveness of spesolimab in people with generalized pustular psoriasis (GPP), a rare and severe skin condition. All 131 participants had already taken spesolimab in a previous study and will continue treatment for up to 5 years. Res…
Phase 2 • Sponsor: LEO Pharma • Aim: Disease control
Last updated Sep 03, 2026 00:00 UTC
-
New shot aims to restore skin color in vitiligo patients
Disease control OngoingThis early-stage trial tests a new drug called TEV-53408 in 38 adults with vitiligo. The main goal is to see if the drug is safe when given as a shot under the skin. Researchers will also look for early signs that it might help bring back skin color. The study lasts 84 weeks, inc…
Phase 1 • Sponsor: Teva Branded Pharmaceutical Products R&D LLC • Aim: Disease control
Last updated Sep 03, 2026 00:00 UTC
-
New pill could tame tough psoriasis
Disease control OngoingThis phase 3 study tests an experimental oral drug, JNJ-77242113, in about 731 adults with moderate to severe plaque psoriasis. Participants receive either the new drug, a placebo, or an active comparator (deucravacitinib) to see how well it clears skin lesions. The main goal is …
Phase 3 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Sep 02, 2026 00:00 UTC
-
New pill shows promise for rare, severe psoriasis
Disease control OngoingThis phase 3 trial tests an oral drug called JNJ-77242113 in 19 people with two rare and severe forms of psoriasis: generalized pustular psoriasis and erythrodermic psoriasis. The study measures how many participants see improvement after 16 weeks of treatment. It is an open-labe…
Phase 3 • Sponsor: Janssen Pharmaceutical K.K. • Aim: Disease control
Last updated Sep 02, 2026 00:00 UTC
-
Can a targeted biopsy replace full neck surgery for High-Risk skin cancer?
Disease control CancelledThis trial tests whether sentinel lymph node biopsy (SLNB) can safely guide treatment for people with high-risk squamous cell carcinoma of the head and neck that has not spread to lymph nodes. Participants receive either SLNB or a more extensive lymph node removal, and researcher…
Phase 2 • Sponsor: University of California, Davis • Aim: Disease control
Last updated Sep 02, 2026 00:00 UTC
-
New hope for immunocompromised skin cancer patients: amivantamab combo tested
Disease control PausedThis phase II trial tests whether a combination of amivantamab and hyaluronidase works as well as cetuximab for treating skin squamous cell carcinoma that has come back or spread. The study enrolls 86 immunocompromised participants, including organ transplant recipients. The goal…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 02, 2026 00:00 UTC
-
New hope for kids with stubborn psoriasis: drug trial shows promise
Disease control OngoingThis study tests a drug called guselkumab in children aged 6 to 17 with chronic plaque psoriasis. The goal is to see if it safely clears skin patches better than a placebo or another treatment. About 120 participants will receive injections and be monitored for 16 weeks.
Phase 3 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Sep 02, 2026 00:00 UTC
-
Can a newer immunotherapy drug keep melanoma from coming back?
Disease control OngoingThis phase III trial compares the drug pembrolizumab (MK-3475) to the current standard treatments—high-dose interferon or ipilimumab—in 1,301 patients with high-risk melanoma that has been surgically removed. The goal is to see if pembrolizumab is better at preventing the cancer …
Phase 3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 30, 2026 00:00 UTC
-
New eczema drug shows promise in Mid-Stage trial
Disease control OngoingThis study tests an experimental drug called JNJ-95597528 in 180 adults with moderate to severe atopic dermatitis (eczema). Participants will receive either the drug or a placebo to see if it improves skin symptoms by at least 75% after 12 weeks. The goal is to control the diseas…
Phase 2 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Aug 30, 2026 00:00 UTC
-
New pill could help psoriasis on scalp, genitals, and palms
Disease control OngoingThis phase 3 study tests an oral drug called JNJ-77242113 in 311 adults with plaque psoriasis affecting special areas like the scalp, genitals, or palms and soles. Participants receive either the drug or a placebo for 16 weeks. The main goal is to see if the drug clears or nearly…
Phase 3 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Aug 30, 2026 00:00 UTC
-
New pill for psoriasis shows promise in large trial
Disease control OngoingThis Phase 3 trial tests an oral drug called JNJ-77242113 in 752 adults with moderate to severe plaque psoriasis. Participants receive either the new drug, a placebo, or an active comparator (Stelara). The study measures how well the drug clears skin lesions at 16 weeks. The goal…
Phase 3 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Aug 30, 2026 00:00 UTC
-
Psoriasis drug stelara under safety watch in kids
Disease control OngoingThis study follows 135 children aged 6 to 17 with moderate to severe plaque psoriasis who are already starting or have recently started treatment with ustekinumab (Stelara). Researchers are monitoring for serious side effects like infections, cancer, and autoimmune issues, as wel…
Sponsor: Janssen-Cilag International NV • Aim: Disease control
Last updated Aug 30, 2026 00:00 UTC
-
Melanoma showdown: which treatment sequence saves more lives?
Disease control OngoingThis phase III trial compares two sequences of treatment for advanced melanoma with a BRAF mutation. One group starts with immunotherapy (ipilimumab and nivolumab) followed by targeted therapy (dabrafenib and trametinib) if needed; the other group starts with targeted therapy the…
Phase 3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 30, 2026 00:00 UTC
-
Can a replacement enzyme keep calcium buildup in check?
Disease control OngoingThis trial tests the long-term safety of a drug called INZ-701 in people with rare genetic conditions that cause abnormal calcium buildup in the body. The study enrolls people who have already received INZ-701 in an earlier trial and want to continue treatment. Researchers will m…
Phase 2 • Sponsor: Inozyme Pharma • Aim: Disease control
Last updated Aug 30, 2026 00:00 UTC
-
Major trial may spare thousands of breast cancer patients from chemo
Disease control OngoingThis large phase 3 trial studied over 5,000 women with hormone receptor-positive, HER2-negative breast cancer that had spread to 1-3 lymph nodes. Participants received standard hormone therapy (tamoxifen or an aromatase inhibitor) either alone or with chemotherapy. The goal was t…
Phase 3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 30, 2026 00:00 UTC
-
Can a blood flow blocker stop breast cancer return?
Disease control OngoingThis large phase III trial tests whether adding bevacizumab (a drug that blocks blood flow to tumors) to standard chemotherapy helps prevent breast cancer from coming back after surgery. About 5,000 patients with lymph node-positive or high-risk lymph node-negative breast cancer …
Phase 3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 30, 2026 00:00 UTC
-
Could a third drug boost melanoma immunotherapy?
Disease control OngoingThis study tests whether adding a drug called sargramostim to the standard immunotherapy combination of nivolumab and ipilimumab helps people with advanced melanoma live longer. About 600 patients with stage III or IV melanoma that cannot be surgically removed are participating. …
Phase 2/3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 30, 2026 00:00 UTC
-
New pill could clear psoriasis in major trial
Disease control OngoingThis phase 3 trial tests an oral drug called JNJ-77242113 for people with moderate to severe plaque psoriasis. About 684 participants will receive either the drug or a placebo to see if it improves skin clearance. The study also includes a withdrawal and retreatment phase to chec…
Phase 3 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Aug 30, 2026 00:00 UTC
-
New stent aims to open blocked veins and heal leg ulcers
Disease control OngoingThis trial is testing a new stent (a small mesh tube) to treat blockages in the large vein in the abdomen (inferior vena cava) and nearby leg veins. The study involves 136 adults with symptoms like leg ulcers, pain, or swelling. Doctors will place the stent to keep the vein open …
Sponsor: W.L.Gore & Associates • Aim: Disease control
Last updated Aug 29, 2026 00:00 UTC
-
Placenta tissue may speed healing of stubborn wounds
Disease control OngoingThis study looks at how safe and effective a dehydrated human placenta tissue product is for healing chronic wounds like diabetic foot ulcers, venous leg ulcers, and pressure ulcers. Researchers will review medical records of 300 adults whose wounds were treated with this product…
Sponsor: Cellution Biologics • Aim: Disease control
Last updated Aug 29, 2026 00:00 UTC
-
New drug litfulo tracked in Real-World hair loss study
Disease control OngoingThis study monitors the long-term safety and effectiveness of the drug Litfulo (ritlecitinib) in 487 patients with alopecia areata, a condition causing patchy hair loss. Researchers will track side effects and measure hair regrowth using the SALT score, aiming for a score of 20 o…
Sponsor: Pfizer • Aim: Disease control
Last updated Aug 29, 2026 00:00 UTC
-
New hope for chronic hives: barzolvolimab shows promise in Long-Term trial
Disease control By invitation onlyThis study looks at the long-term safety and effectiveness of barzolvolimab in adults with chronic spontaneous urticaria (CSU), a condition causing frequent hives and itching. Participants have already completed earlier phase 3 trials. The goal is to see how well the drug control…
Phase 3 • Sponsor: Celldex Therapeutics • Aim: Disease control
Last updated Aug 29, 2026 00:00 UTC
-
New radiation technique may make stem cell transplants safer for scleroderma patients
Disease control OngoingThis early study tests whether a precise type of total body radiation (IMRT) combined with chemotherapy can safely prepare the body for a stem cell transplant in people with severe systemic sclerosis (scleroderma). The goal is to reduce radiation exposure to the lungs and kidneys…
Early phase 1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Aug 29, 2026 00:00 UTC
-
New eczema drug shows promise in Long-Term trial
Disease control OngoingThis long-term study is testing the safety and effectiveness of amlitelimab, an injected drug, in over 1600 people with moderate to severe atopic dermatitis (eczema) who have already taken part in earlier amlitelimab trials. Some participants will stop treatment temporarily to se…
Phase 2/3 • Sponsor: Sanofi • Aim: Disease control
Last updated Aug 29, 2026 00:00 UTC
-
New shot offers hope for Tough-to-Treat eczema
Disease control OngoingThis study tests an injectable drug called amlitelimab for people aged 12 and older with moderate-to-severe eczema that hasn't improved with other treatments. Participants will also use standard steroid creams. The goal is to see if the drug can clear or nearly clear the skin com…
Phase 3 • Sponsor: Sanofi • Aim: Disease control
Last updated Aug 29, 2026 00:00 UTC
-
Engineered immune cells take aim at stubborn blood cancers
Disease control OngoingThis early-phase trial tests a new type of immunotherapy for patients with acute myeloid leukemia (AML) or blastic plasmacytoid dendritic cell neoplasm (BPDCN) that has returned or not responded to treatment. Researchers take a patient's own (or a donor's) T-cells, modify them in…
Phase 1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Aug 28, 2026 00:00 UTC
-
Can a pill keep vitiligo at bay? new study aims to find out
Disease control OngoingThis study tests a daily pill called ritlecitinib in adults and teens with nonsegmental vitiligo, a condition that causes white patches on the skin. The goal is to see if the medicine can maintain or improve skin color regained in a previous study, or if stopping it leads to colo…
Phase 3 • Sponsor: Pfizer • Aim: Disease control
Last updated Aug 28, 2026 00:00 UTC
-
New pill could help kids with severe hair loss regrow hair
Disease control OngoingThis study tests a daily oral medication called ritlecitinib in children aged 6 to 12 with severe alopecia areata, a condition causing significant hair loss. About 208 children will receive either a higher dose, lower dose, or placebo for 6 months. The goal is to see if the drug …
Phase 3 • Sponsor: Pfizer • Aim: Disease control
Last updated Aug 28, 2026 00:00 UTC
-
New hope for HS sufferers: Long-Term drug safety trial underway
Disease control OngoingThis study looks at the long-term safety and effectiveness of the drug povorcitinib for people with moderate to severe hidradenitis suppurativa (HS), a painful skin condition. Participants have already completed 54 weeks of treatment in earlier studies. The goal is to monitor sid…
Phase 3 • Sponsor: Incyte Corporation • Aim: Disease control
Last updated Aug 27, 2026 00:00 UTC
-
A new serum aims to thicken Hair—Will it beat minoxidil?
Disease control OngoingThis trial tests two experimental hair serums against a standard over-the-counter minoxidil treatment in women aged 35 to 70 with mild-to-moderate hair loss. Participants apply a serum to their scalp daily for six months. Researchers will measure changes in hair thickness and vol…
Sponsor: Pacagen, Inc. • Aim: Disease control
Last updated Aug 27, 2026 00:00 UTC
-
Could a daily pill help restore skin color in vitiligo?
Disease control OngoingThis phase 3 trial tests an oral drug called povorcitinib in about 467 adults with nonsegmental vitiligo, a condition causing white patches on the skin. Participants take the drug or a placebo daily for 52 weeks to see if it safely improves skin color on the face and body. The go…
Phase 3 • Sponsor: Incyte Corporation • Aim: Disease control
Last updated Aug 27, 2026 00:00 UTC
-
Can a Three-Pronged attack shrink Hard-to-Treat head and neck cancers?
Disease control OngoingThis phase I trial is testing whether a combination of three treatments — an experimental drug called elimusertib, precise radiation therapy, and the immunotherapy pembrolizumab — can shrink or stabilize recurrent head and neck cancer that cannot be removed by surgery. The study …
Phase 1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 23, 2026 00:00 UTC
-
New eczema drug shows promise in Mid-Stage trial
Disease control OngoingThis study tests an experimental drug called rezpegaldesleukin for adults with moderate-to-severe eczema (atopic dermatitis). About 396 participants will receive either the drug or a placebo for 16 weeks, and those who improve may continue treatment for up to a year. The goal is …
Phase 2 • Sponsor: Nektar Therapeutics • Aim: Disease control
Last updated Aug 23, 2026 00:00 UTC
-
New pill could ease painful skin condition
Disease control OngoingThis phase 3 study tests an oral drug called remibrutinib in 565 people with moderate to severe hidradenitis suppurativa (HS), a chronic skin condition causing painful lumps. Participants receive one of two doses of remibrutinib or a placebo for 68 weeks. The main goal is to see …
Phase 3 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Aug 23, 2026 00:00 UTC
-
Can a hormone replacement tame diabetes and high fats in lipodystrophy?
Disease control Expanded access (ended)This expanded access program provides metreleptin, a synthetic version of the hormone leptin, to people with lipodystrophy who also have diabetes or very high triglycerides. The goal is to see if replacing leptin can help improve blood sugar and fat levels in this rare condition.…
Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated Aug 23, 2026 00:00 UTC
-
Hope for painful skin condition: new pill trial targets hidradenitis suppurativa
Disease control OngoingThis study tests a daily pill called upadacitinib for people with moderate to severe hidradenitis suppurativa (HS), a painful skin condition causing boils in the armpits, groin, and genital area. The trial includes about 1,328 adults and teens who have not improved with standard …
Phase 3 • Sponsor: AbbVie • Aim: Disease control
Last updated Aug 22, 2026 00:00 UTC
-
New psoriasis drug shows promise in Mid-Stage trial
Disease control OngoingThis study tests a new medicine called ORKA-001 for adults with moderate-to-severe plaque psoriasis, a skin condition causing red, scaly patches. About 160 participants will receive either the drug or a placebo to see if it can completely clear the skin by week 16. The goal is to…
Phase 2 • Sponsor: Oruka Therapeutics, Inc. • Aim: Disease control
Last updated Aug 19, 2026 00:00 UTC
-
New eczema drug shows promise in long-term real-world study
Disease control OngoingThis study follows about 772 teenagers and adults with moderate to severe eczema who are taking upadacitinib (Rinvoq) as prescribed by their doctor. Researchers want to see how well the drug controls the disease over two years in everyday medical practice. Participants will have …
Sponsor: AbbVie • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
New shot for eczema shows promise in Mid-Stage trial
Disease control OngoingThis study tests a drug called lutikizumab for people with moderate to severe atopic dermatitis (eczema) that hasn't improved with standard treatments. About 80 participants will receive either the drug or a placebo for 16 weeks, then everyone gets the drug for another 32 weeks. …
Phase 2 • Sponsor: AbbVie • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
New hope for babies with rare calcification disease: first drug trial launches
Disease control OngoingThis study tests a new drug called INZ-701 in up to 16 infants (up to 1 year old) with rare genetic conditions (ENPP1 or ABCC6 deficiency) that cause dangerous calcium buildup in arteries and other problems. The main goal is to check the drug's safety and how the body handles it,…
Phase 1 • Sponsor: Inozyme Pharma • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
Can an immune booster keep melanoma from returning after surgery?
Disease control OngoingThis phase 3 trial is testing whether the immunotherapy drug nivolumab (Opdivo) can prevent melanoma from coming back in people who have had their stage IIB/C melanoma completely removed. About 790 adults and children are randomly assigned to receive either nivolumab or a placebo…
Phase 3 • Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated Aug 09, 2026 00:00 UTC
-
Placenta patch may heal stubborn leg wounds
Disease control By invitation onlyThis study tests whether a patch made from donated human placenta tissue, plus standard wound care, helps close nonhealing venous leg ulcers better than standard care alone. About 70 adults with ulcers present for at least 4 weeks will take part. Those who get standard care first…
Phase 4 • Sponsor: Cellution Biologics • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
Triple immunotherapy attack shows promise for tough skin cancer
Disease control OngoingThis study tests a combination of three immunotherapy drugs (INCMGA00012, INCAGN02385, and INCAGN02390) in 12 adults with advanced Merkel cell carcinoma that continued to grow after standard treatment. The drugs are given by IV to help the immune system fight the cancer. The main…
Phase 2 • Sponsor: University of Washington • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
Can a CBD cream soothe Eczema's relentless itch?
Disease control By invitation onlyThis phase 2 trial is testing whether a 5% cannabidiol (CBD) cream can reduce itching and skin severity in adults with chronic eczema conditions like atopic dermatitis and nummular eczema. About 60 participants will apply the CBD cream or a standard steroid cream for 4 weeks. The…
Phase 2 • Sponsor: Khon Kaen University • Aim: Disease control
Last updated Aug 06, 2026 00:00 UTC
-
Can a biologic drug quiet the relentless itch of prurigo nodularis?
Disease control OngoingThis study follows adults with moderate-to-severe prurigo nodularis—a skin condition marked by intensely itchy nodules—who are starting treatment with dupilumab (Dupixent) as part of their normal care. Researchers will track how well the drug reduces itching and clears skin lesio…
Sponsor: Sanofi • Aim: Disease control
Last updated Aug 02, 2026 00:00 UTC
-
New pill could help regrow hair in severe alopecia
Disease control OngoingThis study tests a daily pill called upadacitinib for people with severe alopecia areata, an immune system attack on hair follicles causing at least 25% scalp hair loss. About 123 teens and adults in Japan will take either the drug or a placebo for up to 104 weeks to see if it sa…
Phase 3 • Sponsor: AbbVie • Aim: Disease control
Last updated Aug 01, 2026 00:00 UTC
-
New antibody aims to calm eczema Flare-Ups from the inside
Disease control OngoingThis study tests an experimental drug called BFB759, a lab-made antibody that blocks several inflammatory signals at once. Researchers want to see if it can reduce redness, swelling, and itching in adults with moderate-to-severe eczema that hasn't improved with creams. About 225 …
Phase 2 • Sponsor: Bluefin Biomedicine, Inc. • Aim: Disease control
Last updated Aug 01, 2026 00:00 UTC
-
New hope for kids with severe eczema: drug trial shows promise
Disease control OngoingThis study tests a drug called lebrikizumab in children aged 6 months to 18 years with moderate-to-severe eczema (atopic dermatitis). The goal is to see if it improves skin condition and reduces itching compared to a placebo. About 367 participants will receive either the drug or…
Phase 3 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Aug 01, 2026 00:00 UTC
-
New eczema drug shows promise for kids in Long-Term trial
Disease control By invitation onlyThis study looks at the long-term safety and effectiveness of lebrikizumab for children aged 6 months to under 18 years with moderate-to-severe atopic dermatitis (eczema). About 310 participants who completed a prior study will receive lebrikizumab for up to 116 weeks. The goal i…
Phase 3 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Aug 01, 2026 00:00 UTC
-
Can a new drug safely control eczema over the long haul?
Disease control By invitation onlyThis trial is investigating whether long-term use of an experimental drug called IMG-007 can safely control moderate-to-severe eczema (atopic dermatitis). The study enrolls people who have already completed a previous IMG-007 trial and will receive the drug as a shot under the sk…
Phase 2 • Sponsor: Inmagene LLC • Aim: Disease control
Last updated Jul 31, 2026 00:00 UTC
-
Psoriasis drug ESK-001 put to the test in Long-Term safety study
Disease control OngoingThis study is checking the long-term safety and effectiveness of the drug ESK-001 (envudeucitinib) for people with plaque psoriasis. It includes 165 adults who have already completed a previous ESK-001 study. Participants will take the drug as an oral tablet and be monitored for …
Phase 2 • Sponsor: Alumis Inc • Aim: Disease control
Last updated Jul 30, 2026 00:00 UTC
-
Can an oral Anti-Inflammatory drug tame a painful skin condition?
Disease control OngoingThis trial is investigating whether upadacitinib, an oral drug that blocks inflammation, can help people with moderate-to-severe hidradenitis suppurativa—a chronic skin disease causing painful lumps, abscesses, and scarring. Fifty adults will take upadacitinib daily for 24 weeks,…
Phase 2 • Sponsor: Peking Union Medical College • Aim: Disease control
Last updated Jul 29, 2026 00:00 UTC
-
Can a JAK-Inhibitor cream recolor white patches caused by cancer treatment?
Disease control OngoingThis study tests whether a topical cream containing ruxolitinib can safely restore skin color in people who develop white patches (vitiligo-like depigmentation) as a side effect of cancer immunotherapy. The cream is applied twice daily for 52 weeks. Researchers will measure how m…
Phase 2 • Sponsor: University of Zurich • Aim: Disease control
Last updated Jul 26, 2026 00:00 UTC
-
New study tracks how a skin disease drug works in everyday life
Disease control OngoingThis study follows 435 adults with moderate to severe hidradenitis suppurativa (a painful skin condition) who are taking secukinumab. Researchers want to see how doctors adjust the dose over two years and how well the treatment controls symptoms like abscesses and pain. The goal …
Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jul 22, 2026 00:00 UTC
-
Gene-Corrected skin cells may offer lasting relief for 'Butterfly Children'
Disease control By invitation onlyThis study follows people with recessive dystrophic epidermolysis bullosa (RDEB), a severe blistering skin disease, who previously received an experimental treatment called EB-101. EB-101 uses gene-corrected skin cells to help wounds heal. Researchers will track wound closure, pa…
Sponsor: Abeona Therapeutics, Inc • Aim: Disease control
Last updated Jul 19, 2026 00:00 UTC
-
New drug RAY121 tested for Long-Term control of autoimmune diseases
Disease control By invitation onlyThis study is a long-term extension of an earlier trial, testing the safety of a drug called RAY121 in people with six different immune system disorders, including antiphospholipid syndrome and immune thrombocytopenia. Participants have already completed four doses of RAY121 and …
Phase 1 • Sponsor: Chugai Pharmaceutical • Aim: Disease control
Last updated Jul 19, 2026 00:00 UTC
-
Could a lighter immunotherapy schedule keep advanced cancers in check?
Disease control OngoingThis trial is for people with advanced cancers who have already responded well to 6 months of standard immunotherapy. It compares continuing the same drugs at the usual frequency versus giving them every 3 months. The goal is to see if the reduced schedule can prevent cancer prog…
Phase 3 • Sponsor: UNICANCER • Aim: Disease control
Last updated Jul 19, 2026 00:00 UTC
-
Psoriasis drug bimekizumab: new study looks at gene changes
Disease control OngoingThis study tests the drug bimekizumab in 89 adults with moderate to severe plaque psoriasis, some of whom also have psoriatic arthritis. Researchers will measure changes in gene activity in skin samples after 48 weeks of treatment. The goal is to understand how the drug affects t…
Phase 3 • Sponsor: UCB Biopharma SRL • Aim: Disease control
Last updated Jul 19, 2026 00:00 UTC
-
Simple change in probe care could prevent painful skin injuries in intensive care
Disease control By invitation onlyThis trial compares repositioning a pulse oximeter probe every 2 hours versus every 4 hours in adult intensive care patients. The goal is to see if more frequent repositioning reduces medical device-related pressure injuries. The study involves 432 patients who are monitored for …
Sponsor: Emine Arici Parlak • Aim: Disease control
Last updated Jul 19, 2026 00:00 UTC
-
Promising drug may halt extra bone formation in rare 'Stone Man' disease
Disease control OngoingThis study tests an experimental drug, garetosmab, in 63 adults with fibrodysplasia ossificans progressiva (FOP), a rare condition where soft tissues turn into bone. The goal is to see if the drug safely reduces new bone growth and painful flare-ups. Participants receive either t…
Phase 3 • Sponsor: Regeneron Pharmaceuticals • Aim: Disease control
Last updated Jul 19, 2026 00:00 UTC
-
Could a parasite drug clear flat warts? new trial investigates
Disease control OngoingThis trial tests whether ivermectin, a drug used for parasitic infections, can treat flat warts (plane warts). Researchers will give some participants ivermectin (by mouth and on the skin) and others a placebo to see if the drug helps clear the warts. The study includes people of…
Phase 2 • Sponsor: Al-Azhar University • Aim: Disease control
Last updated Jul 19, 2026 00:00 UTC
-
Immunotherapy before surgery may cut skin cancer recurrence
Disease control OngoingThis trial tests whether giving the immunotherapy drug pembrolizumab (Keytruda) before surgery can improve outcomes for people with high-risk cutaneous squamous cell carcinoma (cSCC), a common skin cancer. Participants receive pembrolizumab infusions before their planned surgery,…
Phase 2 • Sponsor: Diwakar Davar • Aim: Disease control
Last updated Jul 18, 2026 00:00 UTC
-
Could tree sap heal skin sores? new trial in PNG tests ancient remedy
Disease control OngoingThis study tests whether sap from the Pterocarpus indicus tree can help heal small skin ulcers (sores) in remote areas of Papua New Guinea. 222 people with sores smaller than a dime will get either the plant sap, Savlon antiseptic cream, or no treatment. Researchers will check he…
Phase 2 • Sponsor: Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia • Aim: Disease control
Last updated Jul 18, 2026 00:00 UTC
-
Could a common heart drug boost immunotherapy against melanoma?
Disease control PausedThis trial investigates whether adding propranolol, a beta-blocker typically used for heart conditions, can enhance the effects of the immunotherapy drug pembrolizumab in people with advanced melanoma that cannot be removed by surgery. The study includes two phases: first to find…
Phase 1/2 • Sponsor: Roswell Park Cancer Institute • Aim: Disease control
Last updated Jul 17, 2026 00:00 UTC
-
Brain-Body training may give taekwondo athletes an edge
Disease control OngoingThis study tests whether adding neuro-athletic training—exercises that challenge the nervous system with extra sensory input—to regular taekwondo practice can improve balance, agility, and jumping ability while reducing injury risk. Researchers will compare two groups of 13 athle…
Sponsor: Pamukkale University • Aim: Disease control
Last updated Jul 16, 2026 00:00 UTC
-
Eczema drug shows promise in keeping skin clear for a year
Disease control OngoingThis study tests whether a drug called amlitelimab can keep eczema under control for a full year in people aged 12 and older with moderate-to-severe atopic dermatitis. Participants who already responded to treatment in an earlier study will either continue the drug or receive a p…
Phase 3 • Sponsor: Sanofi • Aim: Disease control
Last updated Jul 12, 2026 00:00 UTC
-
New ointment could ease blistering in rare skin disease
Disease control OngoingThis study tests an ointment called diacerein 1% on people with a rare genetic skin condition (EBS) that causes fragile skin and painful blisters. About 80 participants will apply the ointment daily to see if it clears blisters and reduces pain. The trial is double-blind, meaning…
Phase 2/3 • Sponsor: TWi Biotechnology, Inc. • Aim: Disease control
Last updated Jul 11, 2026 00:00 UTC
-
Engineered immune cells take aim at Hard-to-Treat cancers
Disease control OngoingThis trial investigates a new type of immunotherapy for people with advanced cancers that carry a specific marker called NY-ESO-1. Researchers take a patient's own T cells, modify them in the lab to better recognize and attack cancer cells, and then infuse them back. The study al…
Phase 1/2 • Sponsor: Roswell Park Cancer Institute • Aim: Disease control
Last updated Jul 10, 2026 00:00 UTC
-
New immunotherapy duo aims to stop melanoma recurrence
Disease control OngoingThis phase 3 trial tests whether combining two immunotherapy drugs—fianlimab and cemiplimab—can better prevent melanoma from coming back after surgical removal, compared to the standard drug pembrolizumab. The study enrolls people with high-risk melanoma (stages IIB–IV) who have …
Phase 3 • Sponsor: Regeneron Pharmaceuticals • Aim: Disease control
Last updated Jul 08, 2026 00:00 UTC
-
Fat injections and lasers join forces to fight stubborn scars
Disease control By invitation onlyThis study compares two treatments—nanofat injections and fractional CO2 laser—used alone or together for post-traumatic atrophic scars (depressed scars from injury). Sixty participants receive one of the three approaches. The goal is to see if combining both treatments improves …
Sponsor: Tanta University • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
Could a blood extract save sight? early trial tests PRP for rare eye diseases
Disease control OngoingThis pilot study tests whether injections of platelet-rich plasma (PRP) made from a patient's own blood can help preserve vision in people with retinitis pigmentosa or a related condition called EMAP. Thirty participants receive three injections over four months, and researchers …
Phase 1/2 • Sponsor: Rubens Camargo Siqueira • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
Can your own blood help regrow thinning eyebrows?
Disease control OngoingThis study investigates whether injecting platelet-rich plasma (PRP) from a person's own blood can improve mild to moderate eyebrow thinning. Participants receive either PRP or saline injections into the eyebrows, and changes are tracked through photographs over nine months. The …
Phase 2 • Sponsor: Northwestern University • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
New psoriasis shot shows promise in early trial
Disease control OngoingThis study tests an experimental drug called ORKA-001 in 80 adults with moderate-to-severe plaque psoriasis. Participants receive either ORKA-001 or a placebo injection, and doctors measure how much skin clears up after 16 weeks. The goal is to see if ORKA-001 is safe and effecti…
Phase 2 • Sponsor: Oruka Therapeutics, Inc. • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
Could a common acne gel help stop scarring hair loss?
Disease control OngoingThis early-phase study tests whether azelaic acid gel, a topical medication already used for acne, can help women with central centrifugal cicatricial alopecia (CCCA) — a type of scarring hair loss that mainly affects Black women. Eighteen women will use the gel on their scalp on…
Early phase 1 • Sponsor: Wake Forest University Health Sciences • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
Could a diabetes drug boost immunotherapy in advanced melanoma?
Disease control OngoingThis trial investigates whether adding metformin, a common diabetes drug, to the immunotherapy pembrolizumab (Keytruda) can improve treatment for people with advanced melanoma. The study focuses on reversing metabolic problems inside tumors that may weaken immune cells. Participa…
Phase 1 • Sponsor: Yana Najjar • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
New pill shows promise for severe eczema sufferers
Disease control OngoingThis study tests an oral medication called KT-621 for people aged 12 to 75 with moderate-to-severe atopic dermatitis (eczema). The goal is to see if it reduces skin redness, itching, and affected body area compared to a placebo. The trial lasts 16 weeks with a follow-up open-labe…
Phase 2 • Sponsor: Kymera Therapeutics, Inc. • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
New shot could stop dangerous swelling attacks in HAE
Disease control OngoingThis Phase 3 trial tests whether navenibart, a drug given as a shot under the skin, can prevent attacks in people with hereditary angioedema (HAE). About 145 adults and teens with HAE type 1 or 2 will receive either navenibart or a placebo for 6 months. The main goal is to see if…
Phase 3 • Sponsor: Astria Therapeutics, Inc. • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
New antibody drug aims to calm painful skin condition
Disease control OngoingThis Phase 2 trial tests tibulizumab, a dual-action antibody, in 225 adults with hidradenitis suppurativa (HS), a chronic skin condition causing painful abscesses. Participants first receive either the drug or a placebo for 16 weeks, then everyone gets the drug for another 16 wee…
Phase 2 • Sponsor: Zura Bio Inc • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
Vaccine aims to block return of aggressive breast cancer
Disease control OngoingThis phase 2 trial tests whether a vaccine made from a protein found on many triple-negative breast cancer cells can help prevent the cancer from coming back. Participants receive the vaccine along with an immune booster and a low dose of chemotherapy. The study includes women wi…
Phase 2 • Sponsor: Academic and Community Cancer Research United • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
Could a daily pill help restore skin color in vitiligo?
Disease control OngoingThis Phase 3 study tests ritlecitinib, an oral drug, in adults with nonsegmental vitiligo, a condition causing white patches on the skin. About 1,571 participants will receive either 50 mg, 100 mg of ritlecitinib, or a placebo daily for up to 104 weeks. The goal is to see if the …
Phase 3 • Sponsor: Pfizer • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
One-Time radiation during surgery could spare older breast cancer patients weeks of treatment
Disease control OngoingThis study looks at giving a single dose of radiation directly to the tumor site during breast-conserving surgery in women aged 60 and older with early-stage, hormone-sensitive breast cancer. The goal is to see if this shorter, targeted approach controls the cancer as well as sta…
Sponsor: Institut du Cancer de Montpellier - Val d'Aurelle • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
Immunotherapy drug aims to stop deadly skin cancer's return in high-risk patients
Disease control OngoingThis phase 3 trial tests whether the immunotherapy drug avelumab can keep Merkel cell carcinoma from returning in patients whose cancer has spread to lymph nodes and who have already had surgery or radiation. About 100 adults will receive either avelumab or a placebo every two we…
Phase 3 • Sponsor: University of Washington • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New hope for rare fat disorder: daily leptin shots target blood sugar and fats
Disease control OngoingThis Phase 3 trial tests whether a daily injection of metreleptin (a lab-made leptin hormone) can improve blood sugar and fat levels in people with partial lipodystrophy, a rare condition where fat is distributed abnormally. About 69 participants will receive either metreleptin o…
Phase 3 • Sponsor: Chiesi Farmaceutici S.p.A. • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New antibody drug aims to halt Scleroderma's grip
Disease control OngoingThis Phase 3 trial tests whether the drug divozilimab can reduce skin thickening and protect lung function in people with systemic scleroderma, a rare autoimmune disease. About 152 adults and teens with active disease will receive either the drug or a placebo. The study is double…
Phase 3 • Sponsor: Biocad • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
New hope for rare blistering disease: rituximab vs standard therapy
Disease control OngoingThis study compares two drugs, rituximab and cyclophosphamide, in 92 adults with severe mucous membrane pemphigoid, a rare autoimmune disease that causes painful blisters and scarring on mucous membranes. The goal is to see which treatment is safer and more effective at controlli…
Phase 3 • Sponsor: University Hospital, Rouen • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC
-
New hope for HS sufferers: Long-Term drug trial expands
Disease control By invitation onlyThis study looks at the long-term safety and effectiveness of a drug called sonelokimab for people with moderate to severe hidradenitis suppurativa (HS), a painful skin condition. About 835 adults and teens who completed an earlier sonelokimab study will receive the drug for an e…
Phase 3 • Sponsor: MoonLake Immunotherapeutics AG • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC
-
Could a daily pill help restore skin color in vitiligo?
Disease control OngoingThis Phase 3 trial tests upadacitinib (Rinvoq), an oral immune-calming drug, in about 540 adults and teens with non-segmental vitiligo. Participants take a pill once daily for up to 160 weeks, with some receiving placebo first. The study measures how much skin color returns and t…
Phase 3 • Sponsor: AbbVie • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
Could taking breaks from skin cancer drug keep it working?
Disease control OngoingThis trial tests a new way of taking the drug sonidegib for people with advanced basal cell carcinoma that cannot be surgically removed. Instead of taking the drug continuously, patients who have already achieved a complete response will take it in cycles with breaks (14 days on/…
Phase 2 • Sponsor: Gruppo Oncologico del Nord-Ovest • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
Eczema drug dupilumab tested for Long-Term use in kids
Disease control OngoingThis study looks at the long-term safety of dupilumab (Dupixent) in children aged 6 months to 18 years with atopic dermatitis (eczema). About 880 kids who were in earlier dupilumab studies will continue treatment. Researchers will track side effects and check if a pre-filled pen …
Phase 3 • Sponsor: Regeneron Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New biologic drug netakimab tested in kids with psoriasis
Disease control OngoingThis phase 3 trial tests the drug netakimab in children aged 6 and older with moderate to severe plaque psoriasis. The study compares netakimab to a placebo and also includes an open-label group receiving adalimumab. The main goal is to see if netakimab improves skin symptoms, me…
Phase 3 • Sponsor: Biocad • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
Promising pill may halt vitiligo and bring back pigment
Disease control OngoingThis phase 2 trial tests deucravacitinib, a daily pill that targets the immune system, to see if it can stop vitiligo from spreading and help skin regain its color. About 128 adults with non-segmental vitiligo will take the drug or a placebo for 24 weeks, then some will also rece…
Phase 2 • Sponsor: Centre Hospitalier Universitaire de Nice • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
New drug aims to slow lung damage in rare autoimmune disease
Disease control OngoingThis phase 2 trial tests whether tulisokibart can safely slow lung scarring in people with systemic sclerosis and interstitial lung disease. About 154 participants will receive either the drug or a placebo. The main goal is to see if the drug reduces the yearly decline in lung fu…
Phase 2 • Sponsor: Prometheus Biosciences, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
Promising skin cancer trial pulled before it even started
Disease control CancelledThis study was designed to test a new drug called Resimmune against an oral medication (Zolinza) for people with a type of skin lymphoma called mycosis fungoides. The goal was to see if a single four-day treatment could completely clear skin lesions. However, the trial was withdr…
Phase 2 • Sponsor: Virogen Biotechnology Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC
-
Could monitoring replace surgery for some breast lesions?
Disease control OngoingThis study compares active monitoring (regular checkups without immediate treatment) to surgery for people with low-risk ductal carcinoma in situ (DCIS), a very early form of breast cancer. About 1,000 participants are being followed for two years to see if monitoring is as good …
Sponsor: Alliance Foundation Trials, LLC. • Aim: Disease control
Last updated Jun 27, 2026 12:31 UTC
-
Eczema treatment FURESTEM-AD under Long-Term watch
Disease control OngoingThis study follows 262 people with moderate-to-severe atopic dermatitis (eczema) who received an injection of FURESTEM-AD in an earlier trial. Researchers are checking for long-term side effects and tracking how well the treatment controls eczema symptoms over time. The goal is t…
Sponsor: Kang Stem Biotech Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:31 UTC
-
At-Home light therapy could zap nail fungus
Disease control OngoingThis study tests a new home-use LED light device to treat nail fungus (onychomycosis). Researchers want to find the best light dose and how often to use it. Fifty adults with nail fungus will use the device at home and be monitored for improvement.
Sponsor: Chulalongkorn University • Aim: Disease control
Last updated Jun 27, 2026 12:31 UTC
-
Could two weeks of radiation be enough for breast cancer?
Disease control OngoingThis phase 3 trial compares a standard 3-week radiation course to an experimental 2-week course for women with early-stage breast cancer. About 400 participants who had lumpectomy will receive whole breast radiation plus an extra boost to the tumor site. The study checks if the s…
Phase 3 • Sponsor: Weill Medical College of Cornell University • Aim: Disease control
Last updated Jun 27, 2026 12:30 UTC
-
New drug shows promise for regrowing hair in severe alopecia
Disease control OngoingThis study tests a drug called bempikibart (ADX-914) in 75 adults with severe alopecia areata, a condition causing significant scalp hair loss. In the first part, some participants received the drug and some a placebo to see if it helps hair regrow. The second part gives the drug…
Phase 2 • Sponsor: Q32 Bio Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:30 UTC
-
New daily radiation regimen aims to cut treatment time for breast cancer patients
Disease control OngoingThis study tests a modified radiation schedule for women aged 50 and older with early-stage, low-risk breast cancer. Instead of the standard every-other-day treatment over 10 days, participants receive five daily radiation sessions with a slightly lower dose each day. The goal is…
Phase 2 • Sponsor: Sanford Health • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
New drug trial aims to help teens with painful skin condition
Disease control OngoingThis study tests a drug called sonelokimab in 35 teenagers aged 12 to 17 with moderate to severe hidradenitis suppurativa (HS), a chronic skin condition that causes painful lumps. The main goals are to see how the drug moves through the body and whether it is safe. Researchers wi…
Phase 3 • Sponsor: MoonLake Immunotherapeutics AG • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
New combo treatment for vitiligo shows promise in early trial
Disease control OngoingThis study tests whether injecting carbon dioxide gas (carboxytherapy) alongside standard narrowband UVB light therapy can improve repigmentation in people with stable vitiligo. Fifty-nine participants with symmetrical patches will receive whole-body UVB light, with carboxytherap…
Phase 4 • Sponsor: Kasr El Aini Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:28 UTC
-
Could shorter antibiotic courses be better for hospitalized kids?
Disease control By invitation onlyThis study aims to find out if 5 days of antibiotics works as well as 10 days for children hospitalized with pneumonia, skin infections, or urinary tract infections. About 1,200 children will be randomly assigned to either a 5-day or 10-day course, with some receiving a placebo a…
Phase 4 • Sponsor: University of California, San Francisco • Aim: Disease control
Last updated Jun 27, 2026 12:24 UTC
-
Study to zap resistant melanoma spots with surgery or radiation pulled before start
Disease control CancelledThis study planned to test whether adding surgery, radiation, or electrochemotherapy could help control melanoma tumors that did not shrink with encorafenib + binimetinib combination therapy. It was designed for adults with BRAF-mutated melanoma who had been on the drugs for at l…
Phase 4 • Sponsor: SRH Wald-Klinikum Gera GmbH • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
Could a tiny dose of radiation tame this skin cancer?
Disease control OngoingThis study looks at whether a very low dose of radiation (4 Gy) can effectively control a rare, slow-growing type of skin lymphoma called primary indolent cutaneous B-cell lymphoma. Researchers will review records from 52 patients who received this low-dose treatment to see how l…
Sponsor: Azienda USL Reggio Emilia - IRCCS • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
Transplant patients with skin cancer get new hope from engineered virus
Disease control OngoingThis study tests a treatment called RP1, a modified herpes virus injected directly into skin tumors, in 69 people who have had an organ transplant and now have advanced skin cancer. The goal is to see if the virus can shrink tumors safely without harming the transplanted organ. P…
Phase 1/2 • Sponsor: Replimune, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
Engineered immune cells plus chickenpox vaccine take on childhood cancers
Disease control OngoingThis early-phase study tests a new treatment for advanced osteosarcoma and neuroblastoma that has not responded to standard therapy. Researchers take a patient's own immune cells (T cells), add a gene to help them recognize and attack cancer cells, and combine them with a chicken…
Phase 1 • Sponsor: Baylor College of Medicine • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New eczema drug shows promise in Long-Term trial
Disease control OngoingThis study is testing the long-term safety and effectiveness of a drug called amlitelimab for people aged 12 and older with moderate to severe atopic dermatitis (eczema). Participants receive injections of amlitelimab for up to 5 years, and researchers monitor for side effects an…
Phase 2 • Sponsor: Sanofi • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New drug cocktail aims to shrink melanoma before surgery
Disease control OngoingThis phase II trial tests two drugs, pembrolizumab and lenvatinib, given before surgery to people with stage III melanoma that can be removed. The goal is to see if the combination can shrink or eliminate the tumor before the operation. Twenty-one participants will receive the dr…
Phase 2 • Sponsor: Melanoma Institute Australia • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
Eczema drug trial could mean fewer shots for patients
Disease control OngoingThis study tests the drug lebrikizumab in 520 adults and teens (ages 12+) with moderate-to-severe eczema. Part 1 looks at how well the drug improves skin symptoms over 24 weeks. Part 2 compares a new dosing schedule (every 12 weeks) to the current one (every 4 weeks) to see if it…
Phase 3 • Sponsor: Almirall, S.A. • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New hope for HAE patients: experimental drug aims to slash attack rate
Disease control OngoingThis study tests an experimental drug called BW-20805 in 25 adults with hereditary angioedema (HAE), a condition that causes sudden, painful swelling. The goal is to see if the drug can reduce how often attacks happen over about 6 months. Participants must have had at least 2 att…
Phase 2 • Sponsor: Shanghai Argo Biopharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
New drug hopes to tame hardening skin disease
Disease control PausedThis study tests a new drug called CM-101 for people with systemic sclerosis, a disease that causes skin hardening and organ damage. About 45 adults will receive either the drug or a placebo to check safety and how well the body tolerates it. The goal is to see if CM-101 can redu…
Phase 2 • Sponsor: ChemomAb Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
Real-World check: does new psoriasis pill deliver?
Disease control OngoingThis study looks at how well the drug deucravacitinib works for adults with moderate plaque psoriasis in real-life clinics across China. Researchers will track skin clearance and symptom improvement in 153 people who are just starting the medication. The goal is to see if results…
Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC
-
New study tracks how well secukinumab works for painful skin condition in daily life
Disease control OngoingThis study follows 107 adults in Russia with moderate to severe hidradenitis suppurativa (a chronic skin condition causing painful lumps) who are taking secukinumab as part of their normal care. Researchers will track how many patients see a 55% reduction in disease severity over…
Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC
-
New psoriasis drug shows promise in Long-Term trial
Disease control OngoingThis study looks at the long-term safety and effectiveness of the drug ESK-001 for people with moderate to severe plaque psoriasis. Participants are adults who have already completed a prior ESK-001 study. They will take ESK-001 twice daily for 24 weeks, and some may later switch…
Phase 3 • Sponsor: Alumis Inc • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC
-
New study tests 2-Year dupilumab treatment for Kids' eczema
Disease control OngoingThis study looks at how well dupilumab (Dupixent) works over two years in about 48 children aged 6 to 14 with moderate-to-severe eczema. The main goal is to see if the drug improves the skin's barrier function, measured by water loss through the skin. All participants receive dup…
Phase 4 • Sponsor: Sanofi • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC
-
Immunotherapy drug aims to stop rare skin cancer's return
Disease control OngoingThis study tests whether the immunotherapy drug avelumab can help prevent Merkel cell carcinoma, a rare skin cancer, from returning after initial treatment. About 122 adults with stage I to III Merkel cell carcinoma will receive either avelumab or a placebo. The main goal is to s…
Phase 2 • Sponsor: Melanoma and Skin Cancer Trials Limited • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC
-
Which airway method saves more kids? major trial aims to find out
Disease control PausedThis study tests three ways emergency responders help children breathe: a bag-mask, a throat tube, or a breathing tube. It includes 3,000 children under 18 with cardiac arrest, severe injury, or breathing failure. The goal is to see which method leads to more days alive and out o…
Sponsor: Ohio State University • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
New drug shows promise for controlling rare kidney disorders
Disease control OngoingThis study tests the long-term safety and effectiveness of pegcetacoplan in 100 people with two rare kidney diseases, C3 glomerulopathy and IC-MPGN. Participants previously completed a one-year trial and saw benefit from the drug. The goal is to see if pegcetacoplan can keep redu…
Phase 3 • Sponsor: Apellis Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC
-
FLASH radiotherapy: a Blink-and-You'll-Miss-It cancer treatment?
Disease control OngoingThis study compares a new type of radiation called FLASH, which delivers the dose in less than a second, to standard radiation for treating two common skin cancers: basal cell carcinoma and squamous cell carcinoma. About 60 patients aged 60 and older who cannot have surgery will …
Sponsor: Centre Hospitalier Universitaire Vaudois • Aim: Disease control
Last updated Jun 27, 2026 12:01 UTC
-
New combo therapy aims to halt merkel cell cancer spread
Disease control OngoingThis study tests whether adding radiation therapy (either external beam or a targeted radioactive drug called Lutathera) to the immunotherapy avelumab can help control metastatic Merkel cell carcinoma. About 19 adults with advanced disease will receive avelumab every two weeks fo…
Phase 1/2 • Sponsor: Melanoma and Skin Cancer Trials Limited • Aim: Disease control
Last updated Jun 27, 2026 12:01 UTC
-
New hope for chronic hive sufferers: drug shows promise in major trial
Disease control OngoingThis study tests a new drug called barzolvolimab for people with chronic spontaneous urticaria (CSU), a condition causing long-term hives and itching that doesn't get better with standard antihistamines. About 963 adults will receive either the drug or a placebo to see if it redu…
Phase 3 • Sponsor: Celldex Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
Gene therapy aims to stop painful swelling attacks in hereditary angioedema
Disease control OngoingThis study tests a new treatment called NTLA-2002 for adults with hereditary angioedema (HAE), a condition that causes sudden, painful swelling attacks. The therapy uses gene editing to lower a protein that triggers these attacks. The goal is to see if it is safe and can reduce h…
Phase 1/2 • Sponsor: Intellia Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
New hope for chronic hives: barzolvolimab in Late-Stage trial
Disease control OngoingThis phase 3 study tests barzolvolimab, a new biologic drug, in 976 adults with chronic spontaneous urticaria (CSU) whose hives and itching persist despite antihistamines. Participants receive either barzolvolimab or a placebo by injection. The main goal is to see if the drug red…
Phase 3 • Sponsor: Celldex Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
Gene therapy heals wounds in rare skin disease?
Disease control OngoingThis phase 3 trial tests a gene therapy called FCX-007 for people with recessive dystrophic epidermolysis bullosa, a rare disease that causes fragile skin and painful blisters. The therapy uses the patient's own skin cells, genetically corrected to produce collagen, and injects t…
Phase 3 • Sponsor: Castle Creek Biosciences, LLC. • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC
-
Custom skin patch offers hope for rare blistering condition
Disease control OngoingThis study tests a lab-made skin substitute on one patient with dystrophic epidermolysis bullosa, a rare disease causing fragile skin and chronic wounds. The goal is to see if the graft can reduce wound size and pain. It is an early-stage, single-patient trial, not a cure.
Early phase 1 • Sponsor: CHU de Quebec-Universite Laval • Aim: Disease control
Last updated Jun 27, 2026 11:02 UTC
-
New pill shows promise for Long-Term relief of chronic hives
Disease control OngoingThis study tests the long-term safety and effectiveness of remibrutinib, a daily pill, for adults with chronic spontaneous urticaria (hives). Participants who completed earlier phase 3 trials will either continue on the drug or switch to placebo to see if symptoms return. The goa…
Phase 3 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 11:01 UTC
-
Radiation boost may supercharge immunotherapy in breast cancer
Disease control OngoingThis early-phase trial tests whether adding a single, focused dose of radiation before surgery can make the immunotherapy drug pembrolizumab work better in people with early-stage breast cancer. About 27 participants will receive both treatments, then have surgery to see if the t…
Phase 1/2 • Sponsor: Abramson Cancer Center at Penn Medicine • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
Could a Bacteria-Based injection prevent implant complications?
Disease control By invitation onlyThis study tests whether an inactivated Pseudomonas aeruginosa injection, combined with an iodine wash, can reduce complications like infection and capsular contracture in women undergoing immediate breast reconstruction with implants after cancer surgery. The trial involves 100 …
Sponsor: Jianyi Li • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
New cell combo aims to shrink advanced melanoma
Disease control OngoingThis early-phase trial tests a new treatment for people with advanced melanoma that cannot be removed by surgery or has spread. The therapy uses a patient's own immune cells (tumor-infiltrating lymphocytes) grown in a lab and then given back along with a drug called ANV419 to hel…
Phase 1 • Sponsor: University Hospital, Basel, Switzerland • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC
-
New hope for myositis: early IVIg may boost recovery
Disease control OngoingThis study tests whether adding intravenous immunoglobulin (IVIg) to standard steroid treatment early in myositis helps patients improve faster. Myositis is a group of rare diseases causing muscle inflammation and weakness. The trial includes 44 adults diagnosed within the past y…
Phase 2/3 • Sponsor: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) • Aim: Disease control
Last updated Jun 27, 2026 09:08 UTC
-
New combo therapy targets early skin cancer: hope or hype?
Disease control PausedThis pilot study tests whether combining a targeted drug (mogamulizumab) with ultraviolet light therapy (phototherapy) can better control early-stage mycosis fungoides, a type of skin lymphoma. Twenty adults with stage IA-IIA disease will receive the drug for 8 cycles and add pho…
Early phase 1 • Sponsor: H. Lee Moffitt Cancer Center and Research Institute • Aim: Disease control
Last updated Jun 27, 2026 09:08 UTC
-
Could a daily pill tame severe eczema in kids?
Disease control OngoingThis study tests whether upadacitinib (Rinvoq), a daily pill already used in older patients, can safely improve moderate to severe eczema in children aged 2 to 11 in Japan. About 99 kids will receive either the drug or a placebo, plus a steroid cream, for up to a year. Researcher…
Phase 3 • Sponsor: AbbVie • Aim: Disease control
Last updated Jun 27, 2026 09:08 UTC
-
New hope for kids with rare swelling disorder: daily pill may stop attacks
Disease control OngoingThis study tests a daily medication called berotralstat in 29 children aged 2 to under 12 who have hereditary angioedema (HAE), a condition that causes sudden, painful swelling attacks. The goal is to find the right dose based on weight and to check if it is safe and effective at…
Phase 3 • Sponsor: BioCryst Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 09:07 UTC
-
New biologic shot aims to tame painful skin disease
Disease control OngoingThis early-stage trial tests a single dose of a new biologic drug, SBT777101, in 24 adults with moderate-to-severe hidradenitis suppurativa (a chronic skin condition causing painful abscesses and tunnels). The main goal is to check safety and side effects at increasing dose level…
Phase 1 • Sponsor: Sonoma Biotherapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 09:07 UTC
-
Sound waves instead of surgery: new device tested for vein disease
Disease control OngoingThis study tests whether a device called Sonablate can safely use high-intensity focused ultrasound (HIFU) to treat vein problems like varicose veins, leg ulcers, and certain birth defects. About 30 adults with these conditions will receive the treatment, which does not involve c…
Sponsor: Sonablate • Aim: Disease control
Last updated Jun 27, 2026 09:06 UTC
-
Cancer-Killing virus combined with immunotherapy shows promise in advanced tumors
Disease control OngoingThis Phase 2 trial tests a genetically modified herpes virus (RP1) alone or with the immunotherapy drug nivolumab in people with advanced solid tumors, including melanoma, non-small cell lung cancer, and certain skin cancers. The study aims to see if the combination is safe and c…
Phase 2 • Sponsor: Replimune, Inc. • Aim: Disease control
Last updated Jun 27, 2026 09:05 UTC
-
New daily pill could stop painful swelling attacks for HAE patients
Disease control OngoingThis Phase 3 trial tests whether a once-daily pill called deucrictibant can prevent sudden swelling attacks in people aged 12 and older with hereditary angioedema (HAE). Participants receive either the drug or a placebo for 24 weeks, and researchers count how many attacks occur. …
Phase 3 • Sponsor: Pharvaris Netherlands B.V. • Aim: Disease control
Last updated Jun 27, 2026 09:04 UTC
-
Gene-Fixed skin patches tested for rare 'Butterfly' disease
Disease control OngoingThis trial tests a new approach for recessive dystrophic epidermolysis bullosa (RDEB), a rare genetic condition that causes fragile, blistering skin. Researchers take a small piece of the patient's own skin, fix the faulty gene in a lab, grow it into a larger sheet, and graft it …
Phase 1/2 • Sponsor: Institut National de la Santé Et de la Recherche Médicale, France • Aim: Disease control
Last updated Jun 27, 2026 09:04 UTC
-
Promising breast cancer drug trial pulled before starting
Disease control CancelledThis study aimed to see if the drug trastuzumab deruxtecan worked better than standard CDK4/6 inhibitors for people with a specific advanced breast cancer (ER-positive, HER2-low, non-luminal A). It was designed for adults with metastatic disease. However, the trial was withdrawn …
Phase 3 • Sponsor: Danish Breast Cancer Cooperative Group • Aim: Disease control
Last updated Jun 27, 2026 09:04 UTC
-
Extra radiation boost may cut recurrence risk in early breast cancer
Disease control OngoingThis study looks at women with a very early form of breast cancer called ductal carcinoma in situ (DCIS). After surgery to remove the cancer, all women get radiation to the whole breast. Half also get an extra, stronger dose of radiation right where the cancer was. The goal is to…
Sponsor: Institut du Cancer de Montpellier - Val d'Aurelle • Aim: Disease control
Last updated Jun 27, 2026 09:02 UTC
-
Double immunotherapy before surgery shows promise in early melanoma
Disease control OngoingThis study tests giving two immunotherapy drugs (relatlimab and nivolumab) before surgery to people with high-risk stage II melanoma. The goal is to see if this combination can shrink or eliminate the tumor before it is removed. Twenty adults with residual disease after biopsy ar…
Phase 2 • Sponsor: Melanoma Institute Australia • Aim: Disease control
Last updated Jun 27, 2026 09:02 UTC
-
New study tracks psoriasis drug in Real-World greek patients
Disease control OngoingThis study follows 250 adults in Greece who were recently diagnosed with moderate plaque psoriasis and are starting risankizumab, a drug that calms the overactive immune system. Researchers will measure how much the skin clears up and how quality of life improves over two years. …
Sponsor: AbbVie • Aim: Disease control
Last updated Jun 27, 2026 09:01 UTC
-
Radioactive seeds zap breast cancer in one shot
Disease control OngoingThis study tests a one-time radiation treatment for early-stage breast cancer. After a lumpectomy, tiny radioactive seeds are placed directly into the breast to kill any remaining cancer cells. The goal is to see if this method is safe, works well, and costs less than standard da…
Sponsor: British Columbia Cancer Agency • Aim: Disease control
Last updated Jun 27, 2026 09:01 UTC
-
New hope for chronic leg pain: catheter procedure could reduce Post-Clot disability
Disease control OngoingThis study tests whether a catheter-based procedure can reduce the severity of post-thrombotic syndrome (PTS) — a painful, long-term leg condition that can follow a deep vein clot. About 225 adults with disabling PTS and a blocked iliac vein will receive either the procedure plus…
Sponsor: Washington University School of Medicine • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
Could one year of immunotherapy be enough for advanced melanoma?
Disease control OngoingThis phase 2 trial is testing whether one year of pembrolizumab (an immunotherapy drug) works as well as the standard two-year course for people with advanced melanoma that cannot be surgically removed. The study involves 29 participants in Brazil's public health system and measu…
Phase 2 • Sponsor: Instituto do Cancer do Estado de São Paulo • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
Breast cancer overdiagnosis? landmark trial tests monitoring vs. surgery for Low-Risk DCIS
Disease control OngoingThis study is testing whether women with a very early, low-risk form of breast cancer called DCIS can safely avoid standard treatments like surgery and radiation. Instead, they would simply get a yearly mammogram to monitor the condition. The goal is to see if this 'active survei…
Sponsor: The Netherlands Cancer Institute • Aim: Disease control
Last updated Jun 27, 2026 08:14 UTC
-
Radiation-Free path for Low-Risk breast cancer patients?
Disease control OngoingThis study looks at whether women aged 50 and older with a very low-risk type of early breast cancer (called DCIS) can avoid radiation therapy after having breast-conserving surgery. The goal is to see if the cancer stays away without radiation, reducing unnecessary treatment and…
Sponsor: UNICANCER • Aim: Disease control
Last updated Jun 27, 2026 08:13 UTC
-
New MRI-Guided radiation technique tested for breast cancer treatment
Disease control OngoingThis study compares two types of radiation therapy for women with early-stage breast cancer after lumpectomy. One group receives standard CT-guided radiation, while the other receives a newer MRI-guided approach. The goal is to see if MRI-guided radiation works just as well at pr…
Sponsor: Weill Medical College of Cornell University • Aim: Disease control
Last updated Jun 27, 2026 08:13 UTC
-
Can light therapy boost eczema treatment? new trial tests UVB plus creams
Disease control OngoingThis study tests whether adding narrowband UVB phototherapy (a type of light treatment) to optimized topical therapy (creams, ointments, and skin care advice) helps adults with moderate atopic eczema more than topical therapy alone. About 316 adults whose eczema is not well contr…
Sponsor: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) • Aim: Disease control
Last updated Jun 27, 2026 08:13 UTC
-
New combo therapy before surgery shows promise for rare skin cancer
Disease control OngoingThis study tests whether giving a short course of chemotherapy plus immunotherapy before surgery can improve outcomes for people with Merkel cell carcinoma, a rare skin cancer. About 36 adults with operable tumors will receive one cycle of retifanlimab and platinum-etoposide befo…
Phase 2 • Sponsor: Gruppo Oncologico del Nord-Ovest • Aim: Disease control
Last updated Jun 27, 2026 08:11 UTC
-
Can a common arthritis drug tame stubborn hand eczema?
Disease control OngoingThis study looks at how well methotrexate, a drug often used for arthritis, works for people with hand eczema. Researchers will track 50 patients to see if their skin improves and how their quality of life changes. The goal is to find better ways to manage this chronic skin condi…
Sponsor: Lone Skov • Aim: Disease control
Last updated Jun 27, 2026 08:10 UTC
-
Engineered immune cells take on lupus and scleroderma in first human test
Disease control OngoingThis early-stage study is testing a new treatment called CNTY-101 for people with severe autoimmune diseases like lupus, scleroderma, and inflammatory myopathies that haven't improved with standard therapies. CNTY-101 uses specially engineered immune cells to target and destroy f…
Phase 1 • Sponsor: Century Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:09 UTC
-
Fish skin could help burn victims heal with less pain
Disease control By invitation onlyThis study tests whether a special fish skin graft can help deep burn wounds heal without needing as much skin taken from the patient's own body. About 65 adults with deep partial-thickness burns will receive both the fish skin graft and a standard skin graft on different burn ar…
Phase 4 • Sponsor: Kerecis Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:09 UTC
-
Pharmacists take on heart disease: new study tests community-based risk reduction
Disease control OngoingThis study tests whether a pharmacist-led program can help people reduce their risk of heart disease. Over 1,000 adults with conditions like diabetes, high blood pressure, or obesity are taking part. Pharmacists use a step-by-step guide to assess risk and support lifestyle change…
Sponsor: University of Alberta • Aim: Disease control
Last updated Jun 27, 2026 08:08 UTC
-
Psoriasis drug shows promise for kids in Real-World study
Disease control OngoingThis study follows about 200 children aged 6 to 17 with moderate-to-severe plaque psoriasis who are taking secukinumab (Cosentyx). Researchers want to see how long patients stay on the drug, how well it controls their psoriasis, and how tolerable it is. The study collects data fr…
Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 08:06 UTC
-
New eczema pill shows promise in large trial
Disease control OngoingThis study tests whether a daily pill called upadacitinib, used with a steroid cream, can safely reduce eczema symptoms like itching and redness in teens and adults with moderate-to-severe disease. About 1,500 participants took the pill or a placebo for 16 weeks. The main goals w…
Phase 3 • Sponsor: AbbVie • Aim: Disease control
Last updated Jun 27, 2026 08:06 UTC
-
Lifeline for HAE patients: study offers continued access to promising treatment
Disease control By invitation onlyThis study gives people with hereditary angioedema (HAE) who were in earlier berotralstat trials continued access to the medication. About 139 participants will receive berotralstat and be monitored for side effects. The goal is to keep treating their condition while gathering mo…
Phase 3 • Sponsor: BioCryst Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 08:06 UTC
-
New drug shows promise in preventing hereditary swelling attacks
Disease control OngoingThis study tests the long-term safety and effectiveness of donidalorsen, a drug given as a shot under the skin, to prevent attacks of hereditary angioedema (HAE). HAE causes sudden, painful swelling in various body parts. The trial involves 154 participants who previously complet…
Phase 3 • Sponsor: Ionis Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC
-
Engineered immune cells take on Hard-to-Treat cancers
Disease control OngoingThis early-stage study tests a new treatment called BOXR1030 for people with advanced solid tumors that have a specific marker (GPC3). The treatment uses specially designed immune cells given after chemotherapy to help fight the cancer. The main goals are to check safety and find…
Phase 1/2 • Sponsor: Sotio Biotech Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:02 UTC
-
New psoriasis drug tracked for 5 years in Real-World german study
Disease control OngoingThis study follows 550 adults with moderate-to-severe plaque psoriasis who are starting deucravacitinib in routine German clinics. Over 5 years, researchers will measure how well the drug clears skin and improves quality of life. The goal is to see how the treatment works outside…
Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated Jun 27, 2026 08:01 UTC
-
Eczema drug study for Kids' growth pulled before it started
Disease control CancelledThis study was designed to see if dupilumab (Dupixent), an approved eczema drug, could improve growth and bone strength in children aged 6 to 12 with severe atopic dermatitis. It planned to enroll children whose eczema was not controlled by topical treatments. However, the study …
Phase 4 • Sponsor: Regeneron Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 08:00 UTC
-
Gene therapy for HAE: does it last? new study tracks Long-Term safety
Disease control By invitation onlyThis study follows about 100 people with hereditary angioedema who previously received the gene-editing therapy NTLA-2002. Researchers will monitor side effects and how well the treatment controls swelling attacks over time. The goal is to understand if a single dose can provide …
Sponsor: Intellia Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 08:00 UTC
-
Amniotic grafts show promise for chronic wounds in large Real-World study
Disease control OngoingThis study looks at whether adding four types of amniotic membrane grafts to standard care helps heal chronic wounds like diabetic foot ulcers, venous leg ulcers, and pressure ulcers faster. Researchers will track 2,000 adults to see if wounds close completely within 12 weeks and…
Sponsor: Dynamic Medical Services dba Acesso Biologics • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC
-
Hair loss drug shows promise in Long-Term trial for alopecia areata
Disease control OngoingThis study looks at the long-term safety and effectiveness of a drug called CTP-543 for adults with moderate to severe alopecia areata, a condition that causes patchy hair loss. About 1,000 people who already completed 24 weeks of treatment in a previous CTP-543 trial will contin…
Phase 2/3 • Sponsor: Sun Pharmaceutical Industries, Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC
-
New drug duo aims to stall advanced breast cancer
Disease control OngoingThis study tests a new oral drug, camizestrant, combined with palbociclib against the standard anastrozole plus palbociclib in people with ER-positive, HER2-negative advanced breast cancer who haven't had prior treatment for advanced disease. About 1,370 participants will be foll…
Phase 3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC
-
Could this drug stop the body from turning muscle into bone?
Disease control OngoingThis study tests an experimental drug called andecaliximab in 92 children and adults with fibrodysplasia ossificans progressiva (FOP), a rare genetic condition where soft tissues turn into bone. The goal is to see if the drug can safely reduce new bone growth and flare-ups. Parti…
Phase 2/3 • Sponsor: Ashibio Inc • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC
-
New hope for tough psoriasis spots: tildrakizumab under the microscope
Disease control OngoingThis study looks at how well tildrakizumab works for psoriasis in areas that are often hard to treat, like the scalp, nails, genitals, and palms. About 120 adults with moderate to severe psoriasis will receive tildrakizumab and be followed for up to 52 weeks. The goal is to see i…
Sponsor: Clin4all • Aim: Disease control
Last updated Jun 27, 2026 07:52 UTC
-
New drug hopes to tame rare muscle and skin disease
Disease control OngoingThis study tests a drug called empasiprubart in adults with dermatomyositis, a rare disease causing muscle weakness and skin rash. Three participants receive either the drug or a placebo for 25 weeks, then are followed for 65 more weeks. The goal is to see if the drug is safe and…
Phase 2 • Sponsor: argenx • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC
-
New combo therapy targets hard-to-treat melanoma in early trial
Disease control OngoingThis early-stage trial tests whether adding an experimental treatment (MB097) to the immunotherapy drug pembrolizumab is safe and shows signs of working in people with advanced melanoma that did not respond to standard anti-PD1 therapy. About 41 participants will receive the comb…
Phase 1 • Sponsor: Microbiotica Ltd • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC
-
Could an existing eczema drug help a rare skin condition?
Disease control OngoingThis Phase 2 trial tests dupilumab (Dupixent), an injectable drug already approved for atopic dermatitis, in 70 adults with nummular eczema, a chronic, itchy skin condition. Participants receive either dupilumab or a placebo for several weeks. The study measures changes in eczema…
Phase 2 • Sponsor: Technical University of Munich • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC
-
Real-World dupilumab study aims to ease chronic itch
Disease control OngoingThis study follows 100 adults with prurigo nodularis who are already prescribed dupilumab (Dupixent) by their doctor. Researchers will track why patients start or stop the drug, how well it controls itching and skin bumps, and any hospital visits. The goal is to see how dupilumab…
Sponsor: Sanofi • Aim: Disease control
Last updated Jun 26, 2026 18:00 UTC
-
Can eczema patients safely take less dupilumab? new trial aims to find out
Disease control OngoingThis study looks at whether people with atopic dermatitis (eczema) that has been well-controlled for at least six months can safely take dupilumab less often. About 256 teens and adults will either stick with their usual every-two-week injection or gradually space out doses. The …
Phase 4 • Sponsor: Nantes University Hospital • Aim: Disease control
Last updated Jun 26, 2026 16:13 UTC
-
Hair loss trial pulled before it even started
Disease control CancelledThis trial aimed to test a combination of platelet-rich plasma and stem cells from fat tissue for treating male and female pattern hair loss. It was designed to compare different mixtures injected into the scalp. However, the study was withdrawn before enrolling any participants,…
Phase 1/2 • Sponsor: Healeon Medical Inc • Aim: Disease control
Last updated Jun 26, 2026 16:04 UTC
-
Immunotherapy combo shows promise in aggressive breast cancer trial
Disease control OngoingThis phase II trial is testing whether adding the immunotherapy drug pembrolizumab (Keytruda) to standard chemotherapy can improve outcomes for people with HER2-negative inflammatory breast cancer, a rare and aggressive type. About 52 participants will receive either chemo alone …
Phase 2 • Sponsor: Institut Paoli-Calmettes • Aim: Disease control
Last updated Jun 26, 2026 15:40 UTC
-
Transplant patients get new hope: sirolimus cream may stop facial cancers
Disease control OngoingThis phase 3 trial tests whether a cream containing sirolimus (rapamycin) can prevent facial skin cancers in people who have received an organ transplant. 146 participants apply the cream or a placebo to their face every night for 6 months. The study counts new skin cancers durin…
Phase 3 • Sponsor: Melanoma and Skin Cancer Trials Limited • Aim: Disease control
Last updated Jun 26, 2026 15:07 UTC
-
New keytruda copycat tested in melanoma trial
Disease control OngoingThis study tests whether FYB206, a biosimilar (or copycat) of the cancer drug Keytruda, works similarly in the body. It involves 96 people with stage IIB/IIC or III melanoma that was completely removed by surgery. Participants receive either FYB206 or Keytruda, and researchers co…
Phase 1 • Sponsor: Formycon AG • Aim: Disease control
Last updated Jun 26, 2026 14:08 UTC
-
Shingles shot put to the test in older HIV patients
Disease control OngoingThis study looks at how well the Shingrix vaccine protects against shingles in people over 50 living with HIV, compared to healthy adults of the same age and gender. About 225 participants will receive two doses of the vaccine and be monitored for one year. The goal is to see if …
Phase 4 • Sponsor: Calmy Alexandra • Aim: Disease control
Last updated Jun 26, 2026 13:35 UTC
-
Cameras and ultrasound could take the guesswork out of wound care
Diagnosis OngoingChronic wounds are slow-healing skin injuries often linked to diabetes, poor circulation, or pressure. Doctors usually judge these wounds by eye, which can lead to inconsistent assessments. This pilot study tests whether a combination of non-invasive imaging techniques, including…
Sponsor: Scuola Superiore di Studi Universitari e di Perfezionamento Sant'Anna • Aim: Diagnosis
Last updated Sep 21, 2026 21:00 UTC
-
Glow-in-the-Dark mouth scans could catch cancer early
Diagnosis OngoingThis study tests whether special lights and cameras can help find early signs of mouth cancer in people at high risk. About 338 participants with precancerous spots or conditions like Fanconi anemia will have their mouths examined with fluorescence imaging, which makes abnormal c…
Sponsor: M.D. Anderson Cancer Center • Aim: Diagnosis
Last updated Sep 16, 2026 00:00 UTC
-
Could women test for yeast infections at home? a swab test takes on the lab
Diagnosis OngoingResearchers are comparing the SavvyCheck Vaginal Yeast Test, a rapid swab test women use themselves, against standard vaginal yeast culture done in a lab. The study enrolls women with symptoms such as vaginal itching, discharge, soreness, or burning. The goal is to measure how ac…
Sponsor: Uniformed Services University of the Health Sciences • Aim: Diagnosis
Last updated Sep 12, 2026 00:00 UTC
-
Brain scans could spot hidden cancer spread in breast patients
Diagnosis OngoingThis study is testing whether regular MRI scans of the brain can find cancer that has spread from the breast to the brain, even before symptoms appear. It involves 214 people with metastatic or inflammatory breast cancer. The goal is to see if early detection through screening im…
Sponsor: Brigham and Women's Hospital • Aim: Diagnosis
Last updated Sep 11, 2026 00:00 UTC
-
Laser microscope may speed up skin cancer diagnosis
Diagnosis OngoingThis trial is testing whether a special laser microscope can quickly and accurately examine skin lesions, including benign tumors, basal cell carcinoma, melanoma, and squamous cell cancer. The goal is to see if this technique can determine the extent, structure, and type of a ski…
Sponsor: LMU Klinikum • Aim: Diagnosis
Last updated Aug 28, 2026 00:00 UTC
-
Can a new tracer light up cancer growth?
Diagnosis OngoingThis trial is testing a new imaging tracer called FLT, which is used with a PET scan to measure how fast tumors are growing. The study includes people with various cancers or those awaiting a biopsy for a suspicious mass. The goal is to see if FLT PET imaging can help find and di…
Sponsor: Barbara Ann Karmanos Cancer Institute • Aim: Diagnosis
Last updated Aug 12, 2026 00:00 UTC
-
AI vs. human eye: a new test for measuring bedsores
Diagnosis OngoingThis trial is testing whether an AI system can measure the area of pressure ulcers (bedsores) as accurately as the traditional manual grid-counting method, but in less time. Adults with pressure ulcers will have a transparent grid film placed on their wound, and a single photo wi…
Sponsor: Affiliated Hospital of Nantong University • Aim: Diagnosis
Last updated Aug 06, 2026 00:00 UTC
-
New york program offers extra screening for 100,000 newborns
Diagnosis By invitation onlyScreenPlus is a large pilot program that offers families the option to have their newborn screened for a panel of rare genetic disorders, in addition to standard newborn screening. The study aims to screen 100,000 infants born at eight hospitals in New York. Researchers will eval…
Sponsor: Albert Einstein College of Medicine • Aim: Diagnosis
Last updated Jul 30, 2026 00:00 UTC
-
AI reads skin biopsies to spot hidden lymphomas
Diagnosis OngoingThis study is developing and testing an artificial intelligence model that analyzes images of skin biopsies to tell the difference between malignant lymphomas (like mycosis fungoides) and benign conditions that look similar. The AI will be trained on hundreds of archived slides a…
Sponsor: Cairo University • Aim: Diagnosis
Last updated Jul 17, 2026 00:00 UTC
-
Astrophysics meets dermatology: AI that maps moles like stars to catch melanoma early
Diagnosis OngoingThis study tests an AI tool called MoleGazer that uses total body photography to track moles over time, similar to how astrophysicists map the night sky. The goal is to automatically spot new or changing moles that could be early signs of melanoma. Researchers are recruiting peop…
Sponsor: Oxford University Hospitals NHS Trust • Aim: Diagnosis
Last updated Jul 10, 2026 00:00 UTC
-
New PET tracer may spot hard-to-find breast cancer spread
Diagnosis OngoingThis study tests whether a newer PET scan tracer (68Ga-FAPI-46) is better than the standard one (18F-FDG) at finding how far lobular breast cancer has spread. About 40 adults with untreated lobular breast cancer will get both scans, and doctors will compare how many tumor spots e…
Sponsor: Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer • Aim: Diagnosis
Last updated Jul 09, 2026 00:00 UTC
-
New PET tracer could spot cancers that standard scans overlook
Diagnosis OngoingThis phase 1 trial is testing a new imaging tracer called 68Ga-FAPI-46 to see where it collects in normal and cancerous tissues. About 30 people with various solid tumors or blood cancers will receive the tracer and then undergo a PET/CT scan. The goal is to understand how the tr…
Phase 1 • Sponsor: Jonsson Comprehensive Cancer Center • Aim: Diagnosis
Last updated Jul 04, 2026 00:00 UTC
-
Newborn screening study aims to catch rare diseases at birth
Diagnosis OngoingThis study offers voluntary screening for newborns in North Carolina to detect a wide range of rare health conditions early. Using a small blood sample already collected at birth, the program tests for dozens of disorders, including spinal muscular atrophy, cystic fibrosis, and m…
Sponsor: RTI International • Aim: Diagnosis
Last updated Jul 03, 2026 00:00 UTC
-
Ear injury diagnosis showdown: which grading system wins?
Diagnosis By invitation onlyThis study tests how accurately doctors, nurses, and technicians can diagnose ear barotrauma (pressure injury to the ear) using two different grading systems: the TEED score and the O'Neill Grading System (OGS). Thirty healthcare providers will grade 120 photos of eardrums to see…
Sponsor: Northwell Health • Aim: Diagnosis
Last updated Jun 27, 2026 13:08 UTC
-
New test could prevent unnecessary surgery for common skin precancers
Diagnosis OngoingThis study aims to create a diagnostic test that can tell the difference between precancerous skin lesions (actinic keratoses) that will turn into skin cancer and those that will go away on their own. Researchers will study tissue samples from 140 patients with skin cancer and pr…
Sponsor: Centre Hospitalier Régional Metz-Thionville • Aim: Diagnosis
Last updated Jun 27, 2026 13:00 UTC
-
Gene test may spare melanoma patients unnecessary surgery
Diagnosis OngoingThis study is testing a gene signature (the Merlin Assay) to see if it can accurately predict whether melanoma has spread to nearby lymph nodes. Researchers are enrolling 1,820 newly diagnosed melanoma patients who are scheduled for a sentinel lymph node biopsy. The goal is to de…
Sponsor: SkylineDx • Aim: Diagnosis
Last updated Jun 27, 2026 12:23 UTC
-
New PET tracer could spot hidden cancers
Diagnosis OngoingThis early study tests a new radioactive tracer called 68Ga-FAPI-46, which targets a protein (FAP) found around many tumors. About 26 people with various cancers will get a PET/CT scan using this tracer to see where it goes in the body. The goal is to learn if this tracer can hel…
Phase 1 • Sponsor: Jonsson Comprehensive Cancer Center • Aim: Diagnosis
Last updated Jun 27, 2026 09:02 UTC
-
Could a simple light scan replace the skin pinch test for scleroderma?
Diagnosis OngoingThis study is testing a new, non-invasive imaging technique called spatial frequency domain imaging (SFDI) to measure skin thickness in people with scleroderma, an autoimmune disease that causes skin hardening. Currently, doctors assess skin fibrosis by pinching the skin, which i…
Sponsor: Boston University • Aim: Diagnosis
Last updated Jun 27, 2026 08:11 UTC
-
Can a switch to goat milk formula prevent baby eczema?
Prevention OngoingThis trial compares two types of infant formula to see if one lowers the chance of developing eczema, also called atopic dermatitis. Researchers will enroll over 2,000 healthy full-term babies and feed them either a formula made from whole goat milk or one made from cow's milk. T…
Sponsor: Dairy Goat Co-operative (N.Z.) Limited • Aim: Prevention
Last updated Aug 29, 2026 00:00 UTC
-
Can Eco-Friendly education extend breastfeeding?
Prevention OngoingThis trial tests whether an educational program on sustainable diet and breastfeeding, given before delivery, can increase the number of mothers who exclusively breastfeed for up to six months. The study includes 429 pregnant women and also measures the environmental impact of di…
Sponsor: Fundacio d'Investigacio en Atencio Primaria Jordi Gol i Gurina • Aim: Prevention
Last updated Aug 08, 2026 00:03 UTC
-
New program aims to cut heart risks in psoriasis patients
Prevention OngoingThis study tests whether a dedicated care coordinator can help people with psoriasis or psoriatic arthritis reduce their risk of heart disease. About 520 adults aged 40-75 who do not already take cholesterol medication will receive support to manage risk factors like high cholest…
Sponsor: University of Pennsylvania • Aim: Prevention
Last updated Aug 08, 2026 00:03 UTC
-
Could a sweat session rewrite breast cancer risk?
Prevention OngoingThis study tests whether different amounts of progressive aerobic exercise can reduce risk factors for breast cancer in women who are at high risk. Participants will follow an exercise program, and researchers will measure changes in exercise capacity, body composition, and gene …
Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Prevention
Last updated Aug 07, 2026 00:00 UTC
-
A UV photo and a cheek swab may be the keys to stopping sunburn before it starts
Prevention OngoingThis trial tests whether giving young adults personalized risk information—such as a UV photo of their skin, a genetic test for melanoma risk, and a tailored action plan—can reduce sunburn and encourage sun protection. Over 500 college students who have had recent sunburns or tan…
Phase 3 • Sponsor: University of Utah • Aim: Prevention
Last updated Jul 29, 2026 00:00 UTC
-
Glowing light could spot oral cancer before it starts
Prevention By invitation onlyThis study investigates whether a painless fluorescent light exam can help find early warning signs of oral cancer in adults. Participants complete a health questionnaire and receive a standard oral exam plus a fluorescence scan. The goal is to see if this simple, non-invasive to…
Sponsor: Medical University of Warsaw • Aim: Prevention
Last updated Jul 08, 2026 00:00 UTC
-
New device could stop bedsores before they start in nursing homes
Prevention OngoingThis study tests a handheld device called the SEM Scanner that detects early skin damage up to 10 days before it's visible. Nursing home staff will use it during weekly skin checks to decide when to start prevention care. The goal is to reduce painful pressure injuries, especiall…
Phase 2 • Sponsor: University of California, Los Angeles • Aim: Prevention
Last updated Jun 27, 2026 13:06 UTC
-
Shingles vaccine trial aims to protect vulnerable patients
Prevention OngoingThis study tests the Shingrix vaccine in over 2,000 adults with autoimmune rheumatic diseases like rheumatoid arthritis and lupus, who are at higher risk for shingles. Researchers will compare vaccinated patients to unvaccinated ones to see if the vaccine is safe and triggers a s…
Phase 4 • Sponsor: University of Sao Paulo General Hospital • Aim: Prevention
Last updated Jun 27, 2026 12:29 UTC
-
Color-Coded bedside cards aim to stop pressure injuries in their tracks
Prevention By invitation onlyThis study tests whether placing color-coded cards at the bedside of ICU patients can help nurses prevent pressure injuries (bedsores). The cards use red, yellow, and green to show high, medium, or low risk. Researchers will track 96 patients over 5 days to see if this simple vis…
Sponsor: Saglik Bilimleri Universitesi • Aim: Prevention
Last updated Jun 27, 2026 11:02 UTC
-
New gel could shield breast cancer patients from radiation burns
Prevention OngoingThis study tests a skin gel called GR1014-CG to see if it can prevent or reduce skin irritation caused by radiation therapy after breast cancer surgery. About 273 women will apply the gel before each radiation session for five days. The goal is to find a safe way to protect the s…
Phase 2 • Sponsor: Graegis Pharmaceuticals Ltd • Aim: Prevention
Last updated Jun 27, 2026 07:52 UTC
-
Could fasting before immunotherapy boost skin cancer treatment?
Symptom relief OngoingThis early study tests whether short-term fasting (eating less than 200 calories per day for 3 days) before standard immunotherapy is safe and doable for people with advanced or metastatic skin cancer. Ten participants will receive their usual PD-1/PD-L1 inhibitor drugs along wit…
Phase 1 • Sponsor: University of Southern California • Aim: Symptom relief
Last updated Sep 21, 2026 21:00 UTC
-
Hypnosis for eczema in kids: could it ease the itch?
Symptom relief OngoingThis pilot study tests whether hypnosis can help children aged 8 to 17 with atopic dermatitis (eczema). The experimental group will learn a 'superhero costume' hypnosis technique and practice self-hypnosis at home. The study only aims to see if a larger trial is possible, not to …
Sponsor: Centre Hospitalier Universitaire de la Réunion • Aim: Symptom relief
Last updated Sep 21, 2026 21:00 UTC
-
Can a video-based therapy tame tough behaviors in kids with rare genetic disorders?
Symptom relief OngoingThis study tests a virtual behavioral therapy (Functional Behavioral Training) for children aged 2-12 with genetic syndromes like Fragile X, Angelman, or Rett syndrome who have challenging behaviors. The therapy teaches parents how to identify what triggers problem behaviors and …
Sponsor: Rush University Medical Center • Aim: Symptom relief
Last updated Sep 20, 2026 00:00 UTC
-
New program aims to reduce shame from chronic illness
Symptom relief OngoingThis study tests a group counseling program called Healing HEARTS to help people with conditions like obesity, skin disease, cancer, HIV, diabetes, or chronic pain deal with internalized stigma. Participants will either join the counseling program or a peer support group. The goa…
Sponsor: University of Florida • Aim: Symptom relief
Last updated Sep 18, 2026 00:00 UTC
-
Zapping a leg nerve: can a wearable device help stubborn ulcers heal?
Symptom relief OngoingResearchers are collecting real-world data on the geko device, a small wearable that stimulates the peroneal nerve in the leg, for people with lower-leg ulcers. The registry follows about 2,500 adults who use the device as part of their standard wound care for up to 12 weeks. It …
Sponsor: Firstkind Ltd • Aim: Symptom relief
Last updated Sep 17, 2026 00:00 UTC
-
Could a gauze pad make scars less noticeable? new trial tests 'tie-over' trick
Symptom relief PausedThis study tests whether adding a special gauze dressing (called a tie-over bolster) on top of regular stitches can reduce scarring after surgery on the head or neck. Sixty adults will have their wound closed normally, then half the wound gets the extra bolster. Doctors and patie…
Sponsor: University of California, Davis • Aim: Symptom relief
Last updated Sep 17, 2026 00:00 UTC
-
Green tea compounds could soothe radiation burns in cancer care
Symptom relief By invitation onlyThis Phase 3 trial tests whether catechins (compounds found in green tea) given as a pill or spray can prevent or treat skin damage caused by radiation therapy. About 162 cancer patients will receive either catechins or a placebo, alongside standard care. The goal is to see if th…
Phase 3 • Sponsor: CARLOS FRANCISCO SAAVEDRA GARCIA • Aim: Symptom relief
Last updated Sep 13, 2026 00:00 UTC
-
New eczema drug shows promise in Mid-Stage trial
Symptom relief OngoingThis study tests an experimental drug called APG777 in 470 adults with moderate-to-severe atopic dermatitis (eczema) that hasn't improved with creams. The goal is to see if the drug safely reduces skin redness, itching, and rash. Participants receive either APG777 or a placebo fo…
Phase 2 • Sponsor: Apogee Therapeutics, Inc. • Aim: Symptom relief
Last updated Sep 12, 2026 00:00 UTC
-
Can adding laser to foam therapy clear leg veins better?
Symptom relief OngoingThis trial tests whether combining foam sclerotherapy with a transdermal laser clears spider and reticular leg veins more effectively than foam alone. Researchers will enroll 70 women with these veins on both legs, treating one leg with the combination and the other with foam onl…
Phase 4 • Sponsor: University of Sao Paulo • Aim: Symptom relief
Last updated Sep 05, 2026 00:00 UTC
-
New laser promises Non-Surgical face and neck lift
Symptom relief OngoingThis study tests a special laser to safely lift eyebrows, tighten loose skin under the chin, and reduce wrinkles on the face and jawline. About 40 adults aged 45 to 85 with mild to moderate skin sagging will receive up to three treatments. The goal is to see if the laser can impr…
Sponsor: FA Corporation • Aim: Symptom relief
Last updated Sep 03, 2026 00:00 UTC
-
Promising drug may ease painful genital psoriasis
Symptom relief OngoingThis study tests an injected drug called tildrakizumab for people with moderate to severe genital psoriasis. About 206 adults will receive either the drug or a placebo to see if it clears skin and reduces itching. The goal is to improve comfort and quality of life in this sensiti…
Phase 3 • Sponsor: Sun Pharmaceutical Industries Limited • Aim: Symptom relief
Last updated Sep 03, 2026 00:00 UTC
-
Fizz your face: CO2 gel may speed skin recovery after microneedling
Symptom relief CancelledThis study tests whether a special gel containing carbon dioxide (carboxytherapy paste) can reduce redness and swelling after microneedling, a cosmetic procedure for facial aging. Twenty adults will receive the gel on one side of their face and a placebo on the other, then be mon…
Phase 1/2 • Sponsor: Vanderbilt University Medical Center • Aim: Symptom relief
Last updated Aug 28, 2026 00:00 UTC
-
Which pill works better for acne? new study compares hormone therapy vs antibiotic
Symptom relief OngoingThis study compares two common acne pills for women: spironolactone (a hormone blocker) and doxycycline (an antibiotic). About 350 women aged 16-40 with moderate to severe acne will take one of the two medicines for several weeks. Researchers will count how many pimples clear up …
Phase 4 • Sponsor: University of Pennsylvania • Aim: Symptom relief
Last updated Aug 27, 2026 00:00 UTC
-
New acne cream shows promise in chinese trial
Symptom relief OngoingThis study tests a cream called trifarotene on Chinese people aged 9 and older with moderate acne on the face and upper body. About 561 participants will apply the cream or a placebo daily for 12 weeks. The goal is to see if the cream reduces acne lesions and improves skin appear…
Phase 3 • Sponsor: Galderma R&D • Aim: Symptom relief
Last updated Aug 26, 2026 00:00 UTC
-
Can a Lower-Dose radiation 'Rotisserie' treatment ease skin lymphoma symptoms?
Symptom relief PausedThis trial is testing whether low-dose total skin electron therapy, given while a person stands on a rotating platform, can improve quality of life for people with mycosis fungoides that has returned or not responded to prior treatment. Participants receive standard radiation car…
Sponsor: Vanderbilt-Ingram Cancer Center • Aim: Symptom relief
Last updated Aug 21, 2026 00:00 UTC
-
New cream offers hope for kids with stubborn eczema
Symptom relief OngoingThis study tests a prescription cream called ruxolitinib for children and teens (ages 6 to 17) with moderate eczema. The cream is applied to the skin to reduce redness, itching, and rash. Researchers want to see if it works better than a cream with no medicine and check for side …
Phase 3 • Sponsor: Incyte Corporation • Aim: Symptom relief
Last updated Aug 21, 2026 00:00 UTC
-
New cream could soothe eczema in babies as young as 3 months
Symptom relief OngoingThis study tests a cream called tapinarof on babies and toddlers aged 3 to 23 months with eczema (atopic dermatitis). The goal is to see if it can clear or nearly clear their skin rash. About 180 children will take part, and the cream is compared to a placebo (inactive cream) for…
Phase 3 • Sponsor: Organon and Co • Aim: Symptom relief
Last updated Aug 14, 2026 00:00 UTC
-
New pill could stop dangerous swelling attacks in hereditary angioedema
Symptom relief By invitation onlyThis study tests a pill called deucrictibant for quickly treating swelling attacks in people with hereditary angioedema (HAE), including life-threatening throat swelling. About 150 adults who have had HAE attacks before will take the drug as needed and be monitored for safety and…
Phase 2/3 • Sponsor: Pharvaris Netherlands B.V. • Aim: Symptom relief
Last updated Jul 23, 2026 00:00 UTC
-
Turmeric and blue light may heal blisters in rare skin disease
Symptom relief OngoingThis study tests whether a gel made from curcumin (the active part of turmeric) combined with blue LED light can heal painful mouth blisters in people with epidermolysis bullosa, a rare condition that makes skin and mucous membranes extremely fragile. Twenty participants will rec…
Phase 4 • Sponsor: Universidade Ceuma • Aim: Symptom relief
Last updated Jul 18, 2026 00:00 UTC
-
Could a simple body wash and cream soothe eczema without a prescription?
Symptom relief OngoingThis trial tests whether a daily routine using Rejuvaskin Eczema Body Wash followed by Skin Recovery Cream can improve dryness, roughness, itch, and irritation in adults with eczema-prone skin. Thirty-five participants aged 18 to 65 use the products once daily for 4 weeks and rep…
Sponsor: Rejuvaskin • Aim: Symptom relief
Last updated Jul 16, 2026 00:00 UTC
-
Menthol gloves may offer quick itch relief for eczema sufferers
Symptom relief OngoingThis study tests whether wearing menthol-infused gloves and foot-covers for just five minutes a day can reduce itching in people with atopic dermatitis (eczema). Participants will use the gloves five days on, two days off for four weeks, then stop for two weeks of follow-up. The …
Phase 2 • Sponsor: Taiwan Municipal An-Nan Hospital-China Medical University • Aim: Symptom relief
Last updated Jul 11, 2026 00:00 UTC
-
Sound waves and muscle zaps aim to tighten sagging skin without surgery
Symptom relief OngoingThis study tests whether a single treatment with the SofWave device—which combines high-intensity ultrasound and electrical muscle stimulation—can tighten loose skin and reduce wrinkles by stimulating fibroblasts, the cells that produce collagen. Ten healthy adults aged 35 to 60 …
Sponsor: Sofwave Medical LTD • Aim: Symptom relief
Last updated Jul 10, 2026 00:00 UTC
-
Can sound waves tighten loose skin after weight loss?
Symptom relief OngoingThis study tests whether a device called SofWave, which uses ultrasound energy, can improve loose skin on the face and neck. It includes healthy women aged 30-50 who are starting tirzepatide for weight loss. Half receive SofWave treatments, and the other half serve as a control g…
Sponsor: Sofwave Medical LTD • Aim: Symptom relief
Last updated Jul 10, 2026 00:00 UTC
-
Laser duo aims to make surgical scars less noticeable
Symptom relief OngoingThis study tests whether combining two types of laser treatments—pulsed dye laser (PDL) and fractional photothermolysis—can improve how surgical scars look. Adults who had a dermatologic surgery on their trunk or limbs can join. Some participants receive the laser combination at …
Sponsor: Northwestern University • Aim: Symptom relief
Last updated Jul 03, 2026 00:00 UTC
-
Can adding a simple skin snip boost cellulite treatment?
Symptom relief OngoingThis study tests whether freezing fat cells (cryolipolysis) works better for cellulite when combined with a minor procedure that cuts the fibrous bands pulling down the skin (subcision). Fifteen healthy women with moderate to severe cellulite on both outer thighs will receive one…
Sponsor: Northwestern University • Aim: Symptom relief
Last updated Jul 03, 2026 00:00 UTC
-
Laser vs radiofrequency: which zaps acne scars better?
Symptom relief OngoingThis study compares two devices—ePrime (radiofrequency) and Fraxel (laser)—to see which improves acne scars more. Each participant gets both treatments on different sides of their face, and a blinded dermatologist rates the results. The goal is to find a more effective way to red…
Phase 2 • Sponsor: Northwestern University • Aim: Symptom relief
Last updated Jul 03, 2026 00:00 UTC
-
Cold war on baldness: which scalp cooling method wins for breast cancer patients?
Symptom relief OngoingThis study tests two ways to cool the scalp during chemotherapy to prevent hair loss in women with localized breast cancer. One uses a standard cold cap with a compression bandage, the other a cooling mask. Researchers will compare how well each prevents hair loss, and also look …
Sponsor: Centre Francois Baclesse • Aim: Symptom relief
Last updated Jun 27, 2026 13:07 UTC
-
Could a diet tame chronic hives in children?
Symptom relief By invitation onlyThis trial investigates whether a low-histamine and pseudoallergen-free diet can reduce symptoms like hives and itching in children aged 1 to 18 with chronic spontaneous urticaria. Participants follow the diet for 4 weeks while continuing standard care. Researchers track changes …
Sponsor: Istanbul University • Aim: Symptom relief
Last updated Jun 27, 2026 13:04 UTC
-
Bee glue to the rescue? propolis ointment tested for dry skin
Symptom relief OngoingThis study tests whether ointments made from propolis, a natural substance from honeybees, can improve dry, itchy skin in adults with atopic tendencies. Thirty participants will apply either a propolis ointment or a plain base ointment twice daily for four weeks. Researchers will…
Sponsor: Manara University • Aim: Symptom relief
Last updated Jun 27, 2026 13:01 UTC
-
New drug targets eczema itch even when rash is mild
Symptom relief OngoingThis study tests whether lebrikizumab can reduce itching and skin symptoms in people with moderate eczema who have a high itch burden. About 233 adults and teens will receive the drug for 24 weeks. The main goal is to see if at least 75% of skin symptoms improve or if itch scores…
Phase 4 • Sponsor: Eli Lilly and Company • Aim: Symptom relief
Last updated Jun 27, 2026 12:37 UTC
-
New cream may soothe painful rashes from cancer drugs
Symptom relief OngoingThis study tests whether a cream containing ruxolitinib can improve skin rashes caused by anti-PD1 cancer immunotherapy. About 22 adults with this type of rash will use the cream for 12 weeks. The goal is to see if the rash clears by at least 90%.
Phase 2 • Sponsor: University of Zurich • Aim: Symptom relief
Last updated Jun 27, 2026 12:26 UTC
-
Cancer patients may soon skip hospital trips for skin rashes thanks to telemedicine
Symptom relief By invitation onlyThis pilot study tests whether video consultations can safely assess and manage skin rashes caused by cancer treatments. Researchers will enroll 25 adult cancer patients with mild skin toxicity and see if telemedicine works as well as in-person visits. The goal is to reduce hospi…
Sponsor: Sligo General Hospital • Aim: Symptom relief
Last updated Jun 27, 2026 12:24 UTC
-
Poop pills could ease stomach troubles for scleroderma patients
Symptom relief OngoingThis study tests whether fecal microbiota transplantation (FMT) – giving healthy donor stool in capsules – can safely reduce chronic diarrhea in people with systemic sclerosis. Twenty adults with scleroderma and persistent diarrhea will receive either FMT or a placebo. The main g…
Sponsor: University of Aarhus • Aim: Symptom relief
Last updated Jun 27, 2026 09:10 UTC
-
Light therapy eases mouth sores and skin burns in 33,000 cancer patients
Symptom relief OngoingThis real-world study follows 33,000 cancer patients in France using the CareMin650™ device, which shines light on mouth sores and skin burns caused by chemotherapy or radiation. The goal is to see if this light therapy reduces the severity of these painful side effects. Research…
Sponsor: Centre Hospitalier de Valenciennes • Aim: Symptom relief
Last updated Jun 27, 2026 09:03 UTC
-
New eye drops aim to soothe blistering eye pain in rare skin disease
Symptom relief OngoingThis early-stage study tests whether ELK-003 eye drops can safely reduce eye symptoms in people with two types of epidermolysis bullosa (EB), a rare condition causing fragile skin and blisters. About 20 participants will first be observed without treatment, then receive the eye d…
Phase 1 • Sponsor: Fundación DEBRA Chile, Niños Piel de Cristal • Aim: Symptom relief
Last updated Jun 27, 2026 08:07 UTC
-
New skin spray may heal moisture wounds faster in hospitals
Symptom relief By invitation onlyThis study tests whether a special skin protectant spray (3M Cavilon Advanced) can heal partial-thickness wounds caused by moisture (like from incontinence or stoma leaks) faster and with less pain than usual hospital wound care. About 36 adults in hospitals will be randomly assi…
Sponsor: University Ghent • Aim: Symptom relief
Last updated Jun 27, 2026 08:04 UTC
-
Wound healing device study pulled before starting
Symptom relief CancelledThis study was designed to test the safety and performance of the Avelle negative pressure wound therapy system on chronic wounds, including diabetic foot ulcers and venous leg ulcers. The device uses gentle suction to help wounds heal. However, the study was withdrawn before enr…
Sponsor: ConvaTec Inc. • Aim: Symptom relief
Last updated Jun 27, 2026 08:02 UTC
-
Exercise as medicine: HIIT may soothe lipedema pain
Symptom relief OngoingThis study tests whether 12 weeks of high-intensity interval training (HIIT) can reduce pain and improve quality of life in 62 women with lipedema, a chronic fat disorder causing painful leg swelling. Participants will do HIIT three times a week and then switch to usual care, or …
Sponsor: Norwegian University of Science and Technology • Aim: Symptom relief
Last updated Jun 27, 2026 08:02 UTC
-
Cool cap may keep hair on black chemo patients
Symptom relief OngoingThis study tests if the DigniCap scalp cooling system can prevent hair loss in Black women with early-stage breast cancer undergoing chemotherapy. About 30 participants will use the cooling cap during chemo sessions. The goal is to see if it helps keep hair, reducing the need for…
Sponsor: George Washington University • Aim: Symptom relief
Last updated Jun 27, 2026 07:52 UTC
-
PRP wrist study pulled before it even started
Symptom relief CancelledThis study planned to test whether a platelet-rich plasma (PRP) injection, made from a patient's own blood, could help heal a common wrist ligament injury called TFCC tear. The trial was designed to compare PRP against a placebo in adults with MRI-confirmed tears. However, the st…
Sponsor: Edna Rath • Aim: Symptom relief
Last updated Jun 27, 2026 07:51 UTC
-
Psoriasis patients see Real-World quality of life gains with brodalumab
Symptom relief OngoingThis Canadian study follows about 394 adults with plaque psoriasis who are starting brodalumab as part of their regular care. Over 12 months, researchers measure changes in skin-related quality of life, work productivity, and treatment satisfaction. The goal is to understand how …
Sponsor: Bausch Health Americas, Inc. • Aim: Symptom relief
Last updated Jun 27, 2026 07:51 UTC
-
Foam or liquid? new study tests best way to treat spider veins
Symptom relief OngoingThis study compares two common treatments for spider and reticular veins: liquid sclerotherapy and foam sclerotherapy, both using the drug polidocanol. Some participants will also receive a herbal gel after the procedure. The trial includes 508 adults with mild venous disease (C1…
Sponsor: Kafrelsheikh University • Aim: Symptom relief
Last updated Jun 26, 2026 14:27 UTC
-
Gut bacteria may hold clues to dozens of diseases
Knowledge-focused PausedResearchers are sequencing the gut microbiomes of people with a wide range of conditions, from autism and Alzheimer's to Crohn's disease and multiple sclerosis, to see whether bacterial patterns differ by disease. The study also enrolls healthy participants for comparison. By mat…
Sponsor: ProgenaBiome • Aim: Knowledge-focused
Last updated Sep 21, 2026 21:00 UTC
-
Scientists map skin Cancer's inner workings to decode immunotherapy response
Knowledge-focused OngoingResearchers are studying cutaneous squamous cell carcinoma, a common type of skin cancer, in patients who receive the immunotherapy drug cemiplimab before surgery. The goal is to build a detailed molecular map of the tumor and its surroundings using single-cell sequencing and gen…
Phase 2 • Sponsor: Peter MacCallum Cancer Centre, Australia • Aim: Knowledge-focused
Last updated Sep 21, 2026 21:00 UTC
-
New PET scan tracks immune response in melanoma patients
Knowledge-focused OngoingThis early-phase trial tested a special PET/CT imaging agent, Zirconium Zr 89 Crefmirlimab Berdoxam, to see if it can measure immune activity in tumors of patients with advanced melanoma. Six adults on immunotherapy plus hydroxychloroquine received scans before and after starting…
Early phase 1 • Sponsor: Abramson Cancer Center at Penn Medicine • Aim: Knowledge-focused
Last updated Sep 21, 2026 21:00 UTC
-
Melanoma survivors: new study tracks immunotherapy side effects
Knowledge-focused OngoingThis study follows 126 melanoma survivors who are receiving immunotherapy after surgery. Researchers will track side effects and quality of life for up to 24 months. They will also collect blood samples to look for markers that might predict who gets side effects. The goal is to …
Sponsor: M.D. Anderson Cancer Center • Aim: Knowledge-focused
Last updated Sep 20, 2026 00:00 UTC
-
Scientists dig into tissue samples to unravel lung scarring mystery
Knowledge-focused OngoingThis study collects and analyzes blood, DNA, and tissue samples from 315 adults with pulmonary fibrosis, their relatives, and healthy volunteers. The goal is to learn more about the disease's causes, not to test a new treatment. Researchers hope the findings will guide future the…
Sponsor: National Human Genome Research Institute (NHGRI) • Aim: Knowledge-focused
Last updated Sep 18, 2026 00:00 UTC
-
Which Mini-Implant size works best? new study aims to find out
Knowledge-focused OngoingThis study tests two different diameters (1.6mm and 2mm) of mini-implants placed in the upper jaw to support orthodontic tooth movement. Twenty people receiving braces will get one size on each side of their mouth. Researchers will measure how stable the implants are, how much pa…
Sponsor: University of Baghdad • Aim: Knowledge-focused
Last updated Sep 18, 2026 00:00 UTC
-
New study hopes to outsmart pancreatic cancer by gathering clues
Knowledge-focused OngoingThis study collects health information and test results from 317 people at high risk for pancreatic cancer, including those with cysts, genetic syndromes, or other risk factors. Researchers aim to build a database to find better ways to detect the disease early or prevent it. No …
Sponsor: H. Lee Moffitt Cancer Center and Research Institute • Aim: Knowledge-focused
Last updated Sep 17, 2026 00:00 UTC
-
Can scalp chemistry explain stubborn itching without dandruff?
Knowledge-focused OngoingThis study examines 132 women with itchy scalps, some with dandruff and some without, to see if the two conditions have different biological signatures. Researchers measure skin oils, moisture loss, and clinical signs like redness and dryness. The goal is to understand what drive…
Sponsor: L'Oreal • Aim: Knowledge-focused
Last updated Sep 06, 2026 00:00 UTC
-
New skin scanner could reveal hidden changes in eczema treatment
Knowledge-focused OngoingThis study tests whether a special microscope (reflectance confocal microscopy) can detect skin changes in people with moderate-to-severe eczema who are taking tralokinumab. The drug blocks a protein involved in inflammation and is already known to help eczema. Researchers want t…
Sponsor: Hôpitaux Drôme Nord • Aim: Knowledge-focused
Last updated Sep 05, 2026 00:00 UTC
-
Can your breast MRI reveal hidden cancer risk?
Knowledge-focused OngoingThis study looks at how normal breast tissue appears on MRI and mammogram to see if it can help predict breast cancer risk. Researchers are comparing images and health information from over 2,000 women, including those with and without breast cancer. The goal is to better underst…
Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Knowledge-focused
Last updated Sep 03, 2026 00:00 UTC
-
Researchers dig into past data to uncover M7824's hidden side effects
Knowledge-focused OngoingThis study reviews medical records from 232 adults with cancer who received the immunotherapy drug M7824. The goal is to create a complete list of side effects caused by the drug. By understanding these risks, doctors hope to prevent or reduce them in future cancer treatments.
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Sep 02, 2026 00:00 UTC
-
Coffee warning for nail fungus patients?
Knowledge-focused By invitation onlyThis study checks if drinking caffeine changes blood pressure or heart rate in people taking the antifungal medication terbinafine for nail fungus. Researchers will monitor 52 adults before and after they start the drug. The goal is to understand possible side effects, not to tes…
Sponsor: Weill Medical College of Cornell University • Aim: Knowledge-focused
Last updated Aug 30, 2026 00:00 UTC
-
Cancer treatment gets personal: MATCH trial tests Gene-Guided drugs
Knowledge-focused OngoingThis phase II trial, called MATCH, is testing whether treating cancer based on the genetic makeup of a patient's tumor works better than standard treatments. Over 6,400 adults with advanced solid tumors, lymphomas, or multiple myeloma that have not responded to prior therapy are …
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Aug 30, 2026 00:00 UTC
-
Massive psoriasis registry tracks drug safety over years
Knowledge-focused OngoingThis study is a large registry that follows nearly 16,000 people with psoriasis to monitor the long-term safety of several treatments, including biologic drugs like infliximab and ustekinumab. Participants receive their usual care while researchers track side effects, disease act…
Sponsor: Janssen Scientific Affairs, LLC • Aim: Knowledge-focused
Last updated Aug 30, 2026 00:00 UTC
-
New blood test could spot autoimmune diseases earlier
Knowledge-focused By invitation onlyThis study will use a special blood test called mass spectrometry to look at immune cells in 500 people with various autoimmune diseases and healthy volunteers. The goal is to find patterns that could help doctors diagnose these conditions sooner. No treatments are being tested; …
Sponsor: Peking University People's Hospital • Aim: Knowledge-focused
Last updated Aug 28, 2026 00:00 UTC
-
Can Kids' bodies handle the heat during exercise? a new study investigates
Knowledge-focused By invitation onlyThis study asks how exercise intensity affects body temperature regulation in children and youth (ages 9-16) compared to young adults (ages 20-25). Participants will exercise at light, moderate, and vigorous intensities in a hot room (36°C) while researchers measure heat loss and…
Sponsor: University of Ottawa • Aim: Knowledge-focused
Last updated Aug 26, 2026 00:00 UTC
-
Can we finally outsmart recurrent yeast infections? a new study investigates
Knowledge-focused OngoingThis study aims to understand why some women get recurrent vaginal yeast infections (vulvovaginal candidiasis) and others don't. Researchers will compare the vaginal microbiome, immune markers, and metabolic profiles of women with and without the infection. By identifying key dif…
Sponsor: University Hospital, Antwerp • Aim: Knowledge-focused
Last updated Aug 15, 2026 00:00 UTC
-
Can a vaccine shield transplant patients from shingles?
Knowledge-focused OngoingThis study looks at how the immune system of kidney transplant patients responds to the shingles vaccine and to natural shingles infection. Researchers will track antibody and T-cell levels over time in patients who have had a transplant or are on the waiting list. The goal is to…
Sponsor: Susanne Dam Nielsen, MD, DMSc • Aim: Knowledge-focused
Last updated Aug 14, 2026 00:00 UTC
-
Can immune cells predict herpesvirus danger in transplant patients?
Knowledge-focused OngoingThis study looks at how the immune system's T cells respond to two common herpesviruses—cytomegalovirus (CMV) and varicella-zoster virus (VZV)—in people who have had a liver transplant. Because transplant recipients take drugs that suppress their immune system to prevent organ re…
Sponsor: Susanne Dam Nielsen, MD, DMSc • Aim: Knowledge-focused
Last updated Aug 14, 2026 00:00 UTC
-
Real-World dupixent: does it live up to the hype for eczema?
Knowledge-focused OngoingThis study follows about 955 people aged 12 and older who are starting treatment with Dupixent (dupilumab) for atopic dermatitis, commonly known as eczema. The goal is to see how the drug performs in everyday clinical practice, not just in controlled trials. Researchers will trac…
Sponsor: Sanofi • Aim: Knowledge-focused
Last updated Aug 08, 2026 00:03 UTC
-
Can a gene mutation explain Autism's many faces?
Knowledge-focused OngoingThis study follows individuals with autism who carry a PTEN gene mutation, along with comparison groups, to track changes in thinking, language, and behavior over time. Researchers will also collect blood samples and medical data to build a large database for future studies. The …
Sponsor: Boston Children's Hospital • Aim: Knowledge-focused
Last updated Aug 08, 2026 00:03 UTC
-
Can your genes predict your melanoma risk?
Knowledge-focused OngoingThis study investigates why some people are more susceptible to melanoma, a type of skin cancer. Researchers will compare the genes and sun exposure histories of people who have had multiple melanomas, those with a single melanoma, and similar people without melanoma. By analyzin…
Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Knowledge-focused
Last updated Aug 07, 2026 00:00 UTC
-
Could your diet shape your heart and gut health?
Knowledge-focused OngoingThis study looks at how what people eat relates to heart health, gut bacteria, sleep quality, and thinking skills in Singapore adults aged 21 to 80. Participants will keep a food diary and provide blood and stool samples to measure things like blood pressure, cholesterol, blood s…
Sponsor: National University of Singapore • Aim: Knowledge-focused
Last updated Aug 07, 2026 00:00 UTC
-
Can we predict psoriasis relapse after biologics? a new study digs into the clues.
Knowledge-focused OngoingThis study investigates why some people with plaque psoriasis experience a relapse after treatment with biologic drugs, while others do not. Researchers will compare patients who relapsed with those who did not, looking at factors like age, lifestyle, lab results, and treatment h…
Sponsor: First Affiliated Hospital Xi'an Jiaotong University • Aim: Knowledge-focused
Last updated Jul 30, 2026 00:00 UTC
-
Blood gas clues could predict bedsores in intensive care
Knowledge-focused By invitation onlyThis study looks at whether blood oxygen levels and other blood gas measurements are linked to the risk of developing pressure injuries (bedsores) in intensive care patients. Researchers will monitor 122 adults who have been in the ICU for at least 72 hours, tracking their blood …
Sponsor: Istanbul University • Aim: Knowledge-focused
Last updated Jul 11, 2026 00:00 UTC
-
Light-Activated therapy shows promise for tumor control without surgery
Knowledge-focused OngoingThis study follows people who have received photodynamic therapy (PDT) for various cancers, including head and neck, lung, and skin tumors. PDT uses a light-sensitive drug and a special light to destroy cancer cells while sparing healthy tissue. Researchers will review medical re…
Sponsor: Abramson Cancer Center at Penn Medicine • Aim: Knowledge-focused
Last updated Jul 10, 2026 00:00 UTC
-
Laser light may reveal secrets of skin elasticity
Knowledge-focused OngoingThis study explores how low-level laser therapy (LLLT) affects skin stiffness and thickness. Researchers will use a special imaging system to track tiny skin movements in 20 healthy adults. The goal is to find the best laser settings for future wound healing treatments.
Sponsor: Asia University • Aim: Knowledge-focused
Last updated Jul 04, 2026 00:00 UTC
-
How does your skin bounce back? scientists measure elasticity by age and skin type
Knowledge-focused OngoingThis study looks at how skin elasticity differs by age and skin type, both on normal facial skin and on surgical scars. Researchers will compare people who have had a skin resurfacing or tightening procedure with those who have not. The goal is to create baseline elasticity score…
Sponsor: Northwestern University • Aim: Knowledge-focused
Last updated Jul 03, 2026 00:00 UTC
-
New test could predict immunotherapy success from live tumor samples
Knowledge-focused OngoingThis observational study collects extra tumor tissue from 416 people with various cancers (bladder, kidney, colorectal, head and neck, liver, lung, skin, endometrial) during routine biopsies. The goal is to develop and train a 'live tumor diagnostic platform' that can predict whe…
Sponsor: Elephas • Aim: Knowledge-focused
Last updated Jul 01, 2026 00:00 UTC
-
Do vaccines still work during lymphoma treatment? new study aims to find out
Knowledge-focused OngoingThis study tracks 56 follicular lymphoma patients to see how long their COVID-19 and other vaccine immunity lasts while they receive chemotherapy and maintenance therapy. Researchers will collect blood samples at several time points to measure immune responses. The goal is to und…
Sponsor: Fondazione Italiana Linfomi - ETS • Aim: Knowledge-focused
Last updated Jun 28, 2026 00:00 UTC
-
Real-World study tracks elidel use in asian kids with eczema
Knowledge-focused OngoingThis study is observing how Elidel cream (pimecrolimus) is actually used in South and East Asian children aged 3 months to 12 years with mild to moderate atopic dermatitis (eczema). Researchers are tracking changes in eczema severity, itching, and sleep loss over the treatment pe…
Sponsor: BGP Products Operations GmbH, a Viatris company • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:03 UTC
-
Scientists probe immune secrets of four skin diseases
Knowledge-focused By invitation onlyThis study aims to understand inflammation in four chronic skin conditions: vitiligo, psoriasis, eczema (atopic dermatitis), and alopecia areata. Researchers will collect blood and small skin samples from 450 adults to analyze immune cells called T-cells. The goal is to describe …
Sponsor: University Hospital, Bordeaux • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
Scientists hunt for clues to predict blistering disease severity
Knowledge-focused OngoingThis study looks at 50 people with bullous pemphigoid, a skin condition that causes blisters. Researchers want to see if certain proteins in skin samples and blood markers like IgE and eosinophil counts are linked to how severe the disease is. The goal is to find better ways to m…
Sponsor: Istanbul Training and Research Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
Blood markers could spot hidden skin cancer return
Knowledge-focused OngoingThis study follows 35 people with Merkel cell carcinoma, a rare and aggressive skin cancer, to see if two blood markers (T-antigen antibodies and miR-375) can detect when the cancer comes back. Currently, follow-up relies on physical exams and scans, which may miss early recurren…
Sponsor: University Hospital, Tours • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:08 UTC
-
Massive study tracks 2500 kids from womb to uncover allergy roots
Knowledge-focused OngoingThis study enrolls 2500 pregnant women and follows their children from before birth up to age 3 (or 6 for those who continue). Researchers collect biosamples and environmental data to identify early-life markers and biological pathways that lead to food allergy and atopic dermati…
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:38 UTC
-
Pre-Pregnancy health linked to child development in major singapore study
Knowledge-focused OngoingThis study follows over 1,000 women in Singapore from before pregnancy through their child's early years. Researchers are looking at how nutrition, lifestyle, and emotional health before and during early pregnancy may influence the child's body composition, brain development, and…
Sponsor: KK Women's and Children's Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:38 UTC
-
Blood test may predict melanoma return
Knowledge-focused OngoingThis study is looking at whether a blood test that detects circulating tumor DNA (ctDNA) can help predict if melanoma will come back or spread. Researchers are following 176 adult melanoma patients and comparing ctDNA levels with standard clinical and lab results. The goal is to …
Phase 1/2 • Sponsor: Institute of Oncology Ljubljana • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:37 UTC
-
Eczema drug study pulled before it started
Knowledge-focused CancelledThis study was designed to see how well JAK inhibitors work for adults with moderate-to-severe eczema in real-world settings. It planned to track skin improvement, itching, sleep, and side effects. However, the study was withdrawn before enrolling any participants, so no results …
Sponsor: University Hospital, Lille • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:36 UTC
-
Study reveals pulse oximeters may overestimate oxygen in Darker-Skinned newborns
Knowledge-focused OngoingThis study looks at whether pulse oximeters, which measure oxygen levels, give less accurate readings for newborns with darker skin. Researchers will compare oxygen readings from the device with actual blood oxygen levels in 163 babies of different skin tones. The goal is to find…
Sponsor: University of California, Davis • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:35 UTC
-
Scientists probe Fat-Breast cancer link in 150 patients
Knowledge-focused OngoingThe FATLAS study is looking at how body fat (adiposity) influences breast cancer at both the whole-body and cellular levels. Researchers will enroll 150 breast cancer patients with different body types (lean, overweight, obese) and collect blood, tumor tissue, and body measuremen…
Sponsor: Universitaire Ziekenhuizen KU Leuven • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:34 UTC
-
Mini-Device implanted in tumors could reveal which drug works best
Knowledge-focused By invitation onlyThis early-phase study tests a tiny implantable device that delivers very small amounts of several approved cancer drugs directly into skin cancer tumors. The goal is to see if the device can safely and effectively identify which drug triggers the most cancer cell death in that s…
Early phase 1 • Sponsor: Oliver Jonas • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:34 UTC
-
Prenatal pollution linked to baby eczema?
Knowledge-focused OngoingThis study follows 456 mothers and their children for 5 years to see if certain chemicals in the mother's blood during pregnancy are linked to the child developing eczema. Researchers will check children's skin regularly and track any eczema diagnosis. The goal is to understand p…
Sponsor: Children's Hospital of Fudan University • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:32 UTC
-
New study tracks cancer risk in rare genetic condition
Knowledge-focused PausedThis study follows 430 people with Cowden's disease (a PTEN gene mutation) to better understand their risk of developing cancer. Researchers will track how many participants get cancer over time. The goal is to improve monitoring and care for this high-risk group.
Sponsor: Institut Bergonié • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:32 UTC
-
Scleroderma biomarker study pulled before start
Knowledge-focused CancelledThis study planned to collect extra blood and urine samples from scleroderma patients during their regular check-ups to find biological markers that could predict if their disease would get worse over the next 10 years. The goal was to improve treatment decisions and identify the…
Sponsor: University Hospital, Lille • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:29 UTC
-
Scientists dig into the vaginal microbiome to unlock secrets of recurrent yeast infections
Knowledge-focused OngoingThis study looks at 120 Canadian women to understand why some get repeated yeast infections while others don't. Researchers will compare the vaginal yeast and bacteria of women with their first infection, those with recurrent infections, and those with yeast but no symptoms. Part…
Early phase 1 • Sponsor: University of Manitoba • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:29 UTC
-
New study aims to uncover hidden cancer clues in autoimmune disease
Knowledge-focused OngoingThis study examines blood samples from 50 people with dermatomyositis, an autoimmune disease that raises the risk of cancer. Researchers are looking for new antibodies and immune molecules that might signal which patients are more likely to develop cancer. The goal is to improve …
Sponsor: Azienda USL Reggio Emilia - IRCCS • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:29 UTC
-
450 babies help scientists unlock secrets of healthy eating
Knowledge-focused OngoingThis study follows 450 infants and their families from birth to age 12 to learn how a child's biology and home environment work together to shape eating habits and growth. Researchers collect samples, measurements, and surveys at regular visits. The goal is to understand what inf…
Sponsor: University of Illinois at Urbana-Champaign • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:28 UTC
-
Gene test could personalize breast cancer prevention drug
Knowledge-focused OngoingThis study examines how genetic variations (SNPs) in certain genes influence how well the drug raloxifene works and its side effects in 600 patients with lobular carcinoma in situ (LCIS), a high-risk breast condition. Participants take raloxifene daily, and researchers sequence t…
Phase 2/3 • Sponsor: Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:23 UTC
-
App-Based study tracks quality of life in melanoma patients on targeted therapy
Knowledge-focused OngoingThis study follows 50 adults in the UK with advanced BRAF V600 mutation-positive melanoma who are starting treatment with encorafenib and binimetinib. Instead of a controlled trial, it observes how these drugs work in real-world settings, focusing on patients' quality of life ove…
Sponsor: Pierre Fabre Ltd • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:06 UTC
-
New genetic test may help women with early breast cancer avoid unnecessary treatment
Knowledge-focused OngoingThis study follows 1,500 women with ductal carcinoma in situ (DCIS), a very early form of breast cancer, who have had breast-conserving surgery. Researchers want to see if a genetic test called DCISionRT helps doctors decide whether to add radiation or hormone therapy after surge…
Sponsor: PreludeDx • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:03 UTC
-
Rare disease pregnancy study pulled before it began
Knowledge-focused CancelledThis study was designed to track pregnancies in women with rare autoimmune and systemic diseases to understand complications and improve care. It planned to enroll women with conditions like lupus, rheumatoid arthritis, and scleroderma. However, the study was withdrawn before any…
Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:01 UTC
-
Pedaling against cancer: exercise may boost immunotherapy
Knowledge-focused OngoingThis small pilot study is testing whether a 30-minute stationary bike ride on the same day as immunotherapy can help the treatment work better for people with skin cancers like melanoma. The study involves 12 patients and focuses on whether this exercise plan is practical and saf…
Sponsor: AdventHealth Translational Research Institute • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:00 UTC
-
New study aims to find safe scabies treatment for toddlers
Knowledge-focused OngoingThis study looks at how well a single dose of ivermectin works in children under 5 with scabies. Researchers want to make sure the dose is safe and effective for this age group. About 120 children in Laos will take part, and the study will measure drug levels in the blood.
Phase 2 • Sponsor: Murdoch Childrens Research Institute • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:00 UTC
-
Could a Baby-Friendly ivermectin formula beat scabies?
Knowledge-focused PausedThis trial compares a new ivermectin powder mixed with infant formula to the standard tablet in 52 healthy adults. The goal is to see if the new formulation is absorbed similarly, tastes better, and causes no new side effects. Results will guide future use in children with scabie…
Phase 1 • Sponsor: Murdoch Childrens Research Institute • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:03 UTC
-
15,000 skin patients enrolled in massive Real-World treatment study
Knowledge-focused OngoingThis study follows 15,000 adults and children with skin conditions like eczema, psoriasis, and vitiligo to see how well current and new treatments work in real doctor visits. It does not test a new drug but instead collects information to help doctors understand which treatments …
Sponsor: Target PharmaSolutions, Inc. • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:03 UTC
-
Scratching the surface: study explores skin Irritation's role in psoriasis
Knowledge-focused CancelledThis study aimed to understand why psoriasis and lichen planus often appear on skin that is rubbed or irritated, like from tight clothing. Researchers planned to irritate a small patch of skin in people with these conditions and healthy volunteers, then take skin samples to study…
Sponsor: Marie-Charlotte Brüggen • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:02 UTC
-
5,000 patients to help reveal which wound dressings heal best
Knowledge-focused By invitation onlyThis observational registry will follow 5,000 adults with various wounds—like diabetic foot ulcers, burns, or surgical wounds—to see how different treatments (e.g., hydrocolloid, foam, silver dressings) perform in everyday medical settings. Researchers will measure wound healing,…
Sponsor: Siddhey LLC • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:01 UTC
-
Study comparing Needle-Based breast lesion removal to surgery withdrawn before starting
Knowledge-focused CancelledThis study aimed to compare a less invasive procedure called vacuum-assisted excision (VAPE) to standard surgery for removing non-cancerous but high-risk breast lesions. The goal was to see if VAPE worked as well, was safer, and left better cosmetic results. However, the study wa…
Sponsor: London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:00 UTC
-
New study tracks Dupilumab's Real-Life impact on kids with severe eczema
Knowledge-focused OngoingThis study follows 143 children aged 6 months to 11 years with severe atopic dermatitis (eczema) who are starting treatment with dupilumab in Spain. Researchers will observe how the drug is used in everyday practice, its effectiveness, and any side effects over two years. No extr…
Sponsor: Sanofi • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:08 UTC
-
Fatty liver and psoriasis study pulled before it started
Knowledge-focused CancelledThis study aimed to understand the link between non-alcoholic fatty liver disease (NAFLD) and psoriatic disease (psoriasis and psoriatic arthritis) in overweight adults. Researchers planned to use the drug guselkumab (Tremfya) to see if it improved both conditions. However, the t…
Sponsor: University of California, San Diego • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:07 UTC
-
Scientists hunt for hidden genes behind aortic aneurysms
Knowledge-focused OngoingThis study aims to uncover the genetic roots of aortic aneurysms and valve disease by analyzing tissue and blood samples from 3,000 participants. Researchers will look for new disease-causing genes and factors that affect disease severity. The goal is to build a biorepository to …
Sponsor: Yale University • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:04 UTC
-
20-Year study to unlock secrets of pregnancy and child health
Knowledge-focused OngoingThis study follows about 1,200 mothers from early pregnancy and their children for at least 20 years. Researchers want to learn how genetics, diet, lifestyle, and environment during pregnancy and early childhood affect the risk of metabolic and mental health conditions later in l…
Sponsor: National University Hospital, Singapore • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:03 UTC
-
Fiber fix: diet study hopes to boost cancer immunotherapy
Knowledge-focused OngoingThis study looks at whether eating a high-fiber diet can change the gut bacteria of people with advanced melanoma who are receiving standard immunotherapy. About 50 participants will be randomly assigned to either a high-fiber or a healthy control diet for a set period. The main …
Phase 2 • Sponsor: M.D. Anderson Cancer Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:00 UTC
-
Patients rate their symptoms after starting secukinumab for hidradenitis suppurativa
Knowledge-focused OngoingThis study follows 192 adults with hidradenitis suppurativa (a painful skin condition) who are starting secukinumab as part of their normal care. Researchers will ask patients to rate their pain, oozing, and bad smell after 12 months. The goal is to understand how the drug affect…
Sponsor: Novartis Pharmaceuticals • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:00 UTC
-
Breast Milk's hidden clues: could MicroRNAs predict baby allergies?
Knowledge-focused OngoingThis study followed 221 breastfeeding mothers and their babies to see if small molecules called microRNAs in breast milk are linked to allergies, eczema, or wheezing in the first year of life. Researchers measured these molecules in milk samples and tracked babies' health. The go…
Sponsor: Milton S. Hershey Medical Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:00 UTC
-
Danish study checks skin cancer patients years after radiation
Knowledge-focused By invitation onlyThis study invites 2,900 adults who had radiotherapy for non-melanoma skin cancer on the head or neck between 2020 and 2024 to a follow-up visit at least two years later. Participants will fill out a questionnaire about how the treated area looks and have their skin examined. The…
Sponsor: University of Aarhus • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:11 UTC
-
New hospital program aims to cut unnecessary antibiotics for kids
Knowledge-focused OngoingThis study tests a 'discharge stewardship bundle' to help doctors prescribe the right antibiotics for the right duration when children leave the hospital. Over 1,100 children with pneumonia, urinary tract infections, or skin infections will be followed. Doctors receive feedback r…
Sponsor: Children's Hospital of Philadelphia • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:09 UTC
-
Parents' stories sought to improve care for children with rare birthmarks
Knowledge-focused By invitation onlyThis study aims to understand what parents go through when their child is born with a large or giant congenital melanocytic nevus (a type of birthmark). Researchers will interview 30 parents in France to learn about their experiences and find ways to better support them. The stud…
Sponsor: Central Hospital, Nancy, France • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:07 UTC
-
Real-world dupixent study monitors eczema patients for years
Knowledge-focused OngoingThis study follows 858 people aged 12 and older with atopic dermatitis (eczema) who are starting treatment with Dupixent. Researchers will collect information on their medical history, skin symptoms, and quality of life over time to see how the medicine works in everyday practice…
Sponsor: Regeneron Pharmaceuticals • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:07 UTC
-
Smartphone app study to track rare swelling attacks cancelled
Knowledge-focused CancelledThis study aimed to learn more about the unpredictable swelling attacks in people with bradykinin-mediated angioedema, a rare condition that can cause life-threatening airway swelling. Participants would have used a smartphone app daily to report attacks and possible triggers. Th…
Sponsor: University Hospital, Lille • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:06 UTC
-
Gene hunt in lobular breast cancer could personalize care
Knowledge-focused OngoingThis study looks at 800 people with a type of breast cancer called lobular breast cancer. Researchers are searching for inherited gene changes that may raise cancer risk. Depending on the gene found, patients may get closer monitoring or preventive surgery. The goal is to tailor …
Sponsor: European Institute of Oncology • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:01 UTC
-
10 kids with melanoma tracked for years after drug treatment
Knowledge-focused OngoingThis study follows 10 children in the Netherlands who received ipilimumab for advanced melanoma that had spread or could not be removed. Researchers are looking at long-term side effects and patient characteristics. The goal is to understand how safe the drug is over time in youn…
Sponsor: Bristol-Myers Squibb • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:58 UTC
-
Blood test may predict cancer treatment success
Knowledge-focused OngoingThis study aims to create a tool that can predict whether a cancer patient will benefit from their prescribed therapy. Researchers are analyzing blood samples from 10,000 people with advanced lung cancer or melanoma before and during treatment. The goal is to develop an algorithm…
Sponsor: OncoHost Ltd. • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:54 UTC
-
New study tests if help with housing, food, or transport can cut missed arthritis appointments
Knowledge-focused OngoingThis study looks at whether helping people with inflammatory arthritis address social needs—like food, housing, or transportation—can reduce missed doctor visits. About 100 adults with conditions like rheumatoid arthritis or lupus who have missed appointments in the past year wil…
Sponsor: Brigham and Women's Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:54 UTC
-
Psoriasis 'Memory' targeted in new skin study
Knowledge-focused OngoingThis study looks at whether combining a medicated foam (Enstilar) with ultraviolet light therapy can change immune cells in psoriasis skin that may 'remember' the disease and cause it to return. Researchers will take skin samples from 12 adults with stable plaque psoriasis before…
Phase 4 • Sponsor: Aarhus University Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:53 UTC
-
Eczema cream safety watch: 8,000 kids monitored for a decade
Knowledge-focused OngoingThis study follows 8,000 children aged 2 to 17 with eczema who have used Elidel cream (pimecrolimus 1%). Over 10 years, researchers track how many develop cancer, especially lymphoma and thyroid cancer. The goal is to see if the cream raises cancer risk. No new treatment is given…
Sponsor: Bausch Health Americas, Inc. • Aim: Knowledge-focused
Last updated Jun 26, 2026 18:42 UTC